


# Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update June 01- June 07, 2020,

Dr. Peter J. Lansberg MD, PhD

## ***Weekly COVID-19 Literature Update***

will keep you up-to-date with all recent PubMed publications  
categorized by relevant topics

## **COVID-19 publications - Week 23 2020** 899 Publications

### **PubMed based Covid-19 weekly literature update**

For those interested in receiving weekly updates  
click [here](#)

For questions and requests for topics to add send an e-mail  
[lansberg@gmail.com](mailto:lansberg@gmail.com)

### **Reliable on-line resources for Covid 19**

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

## **Guidelines**

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

## **Trials & Registries**

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

## **Mainstream Media**

[Billionaire scientist's COVID-19 vaccine selected for monkey tests \(Science\)](#)

[How Iceland Beat the Coronavirus \(New Yorker\)](#)

[Iran's rapid rise in Covid-19 cases stokes fears of the second wave \(Guardian\)](#)

[Malaria Drug Did Not Prevent COVID Infections, Study Finds \(NYT\)](#)  
[Man Behind Sweden's Controversial Virus Strategy Admits Mistakes \(Bloomberg\)](#)  
[Blood vessel attack could trigger coronavirus' fatal 'second phase' \(Science\)](#)  
[Surgisphere: governments suspect data from tiny US company \(Guardian\)](#)  
[Genes May Leave Some People More Vulnerable to Severe Covid-19 \(NYT\)](#)  
[The pandemic's first major research scandal erupts \(Science\)](#)  
[The Lancet has made one of the biggest retractions in modern history \(Guardian\)](#)  
[Half of Coronavirus Spread May Traced to People Without Any Symptoms \(TIMES\)](#)  
[Coronavirus crowds out other research papers \(Nature index\)](#)  
[Important Mysteries About Coronavirus Endure \(NYT\)](#)  
[The search for a COVID-19 vaccine is gaining momentum \(S. Diego Union Tribune\)](#)

## KeyArticles

1. **COVID-19: the vasculature unleashed.** *Nat. Rev. Immunol.* 2020; Teuwen LA, Geldhof V, Pasut A, Carmeliet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32439870>
2. **Cholesterol: A new game player accelerating endothelial injuries caused by SARS-CoV-2?** *Am J Physiol Endocrinol Metab* 2020; Cao X, Yin R, Albrecht H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501731>
3. **The role of high cholesterol in age-related COVID19 lethality.** bioRxiv preprint doi: <https://doi.org/10.1101/2020.05.09.086249>; Hao Wang, Zixuan Yuan, Mahmud Arif Pavel, Scott B. Hansen
4. **Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV (or SARS-CoV-2) Infection.** *J Med Virol* 2020; Zhuang MW, Cheng Y, Zhang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497323>
5. **The immune system and COVID-19: Friend or foe?** *Life Sci* 2020:117900 Yazdanpanah F, Hamblin MR, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502542>
6. **Endothelial cell infection and endotheliitis in COVID-19.** *The Lancet* 2020; 395:1417-1418 Varga Z, Flammer AJ, Steiger P *et al.*
7. **Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients.** *Clin Microbiol Infect* 2020; Van Elslande J, Houben E, Depypere M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473953>
8. **Approach to Acute Cardiovascular Complications in COVID-19 Infection.** *Circ Heart Fail* 2020; Ranard LS, Fried JA, Abdalla M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500721>

9. **Biomarkers associated with COVID-19 disease progression.** Crit. Rev. Clin. Lab. Sci. 2020:1-11Ponti G, Maccaferri M, Ruini C *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32503382>
10. **Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement from the Cardiac Society of Australia and New Zealand (CSANZ).** Heart Lung Circ. 2020; Nicholls SJ, Nelson M, Astley C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473781>
11. **COVID-19 Related Coagulopathy: A Distinct Entity?** J Clin Med 2020; 9Marchandot B, Sattler L, Jesel L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486469>
12. **Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).** Vasa 2020:1-5Linnemann B, Bauersachs R, Grebe M *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32501145>
13. **Renin-Angiotensin-System (RAS) and COVID-19 - On the Prescription of RAS Blockers.** Deutsche Medizinische Wochenschrift 2020; 145:682-686Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F.
14. **Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.** Eur Heart J 2020; Gao C, Cai Y, Zhang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498076>
15. **Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.** BMJ 2020; 369:m1985Docherty AB, Harrison EM, Green CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32444460>

---

## Basic Science (27 articles)

1. **ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy.** Aging (Albany NY) 2020; 12Asselta R, Paraboschi EM, Mantovani A, Duga S.  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32501810>
2. **Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors.** Allergy 2020; Radzikowska U, Ding M, Tan G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496587>
3. **Related molecular mechanisms of COVID-19, hypertension, and diabetes.** Am J Physiol Endocrinol Metab 2020; 318:E881Akkus E, Sahin M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479159>
4. **S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19.** Arch Med Res 2020; Arafah A, Ali S, Yattoo AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493626>
5. **Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2.** Arch Med Res 2020; Satarker S, Nampoothiri M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493627>
6. **Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.** Biomed. Pharmacother. 2020; 128:110296Ghafouri-Fard S, Noroozi R, Vafaee R *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32480226>
7. **Interaction of the prototypical alpha-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.** Comput. Biol. Chem. 2020; 87:107292Liang J, Pitsillou E, Karagiannis C *et al.*  
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32485652>

8. **COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice.** *Hum Genomics* 2020; 14:20Lutz C, Maher L, Lee C, Kang W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498696>
9. **Human Gene Sequences in SARS-CoV-2 and Other Viruses.** *In Vivo* 2020; 34:1633-1636Lehrer S, Rheinstein PH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503822>
10. **SARS-CoV-2 orf1b Gene Sequence in the NTNG1 Gene on Human Chromosome 1.** *In Vivo* 2020; 34:1629-1632Lehrer S, Rheinstein PH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503821>
11. **Unfolding SARS-CoV-2 viral genome to understand its gene expression regulation.** *Infect Genet Evol* 2020:104386Dinka H, Milkesa A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473977>
12. **Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach.** *Infect Genet Evol* 2020:104389Lokman SM, Rasheduzzaman MD, Salauddin A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502733>
13. **SARS-CoV-2 molecular and phylogenetic analysis in COVID-19 patients: A preliminary report from Iran.** *Infect Genet Evol* 2020:104387Tabibzadeh A, Zamani F, Laali A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485332>
14. **A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2.** *Int J Biol Macromol* 2020; Wang M, Fu T, Hao J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485251>
15. **Antiviral Effects of Probiotic metabolites on COVID-19.** *J Biomol Struct Dyn* 2020:1-11Anwar F, Altayb HN, Al-Abbasi FA *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475223>
16. **Virtual Screening-Driven Drug Discovery of SARS-CoV2 Enzyme Inhibitors Targeting Viral Attachment, Replication, Post-Translational Modification and Host Immunity Evasion Infection Mechanisms.** *J Biomol Struct Dyn* 2020:1-23Quimque MTJ, Notarte KIR, Fernandez RAT *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476574>
17. **Evidence for mutations in SARS-CoV-2 Italian isolates potentially affecting virus transmission.** *J Med Virol* 2020; Benvenuto D, Demir AB, Giovanetti M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492183>
18. **Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing.** *J Med Virol* 2020; Chan WM, Ip JD, Chu AW *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501535>
19. **Letter to the Editor: A Missing Link between SARS-CoV-2 and the Eye?: ACE2 Expression on the Ocular Surface.** *J Med Virol* 2020; Grajewski RS, Rokohl AC, Becker M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497334>
20. **Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in Lung cancer.** *J Med Virol* 2020; Sagkan RI, Akin-Bali DF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492203>
21. **Virtual screening, ADMET, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.** *J Recept. Signal Transduct. Res.* 2020:1-8Maurya SK, Maurya AK, Mishra N, Siddique HR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476594>
22. **Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.** *Life Sci* 2020:117905Banu N, Panikar SS, Leal LR, Leal AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504757>
23. **What would Sergio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?** *Med. Hypotheses* 2020; 143:109886Nicolau LAD, Magalhaes PJC, Vale ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504925>
24. **Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.** *Nanomaterials (Basel)* 2020; 10Nasrollahzadeh M, Sajjadi M, Soufi GJ *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486364>
25. **The origin of SARS-CoV-2 in Istanbul: Sequencing findings from the epicenter of the pandemic in Turkey.** *North Clin Istanb* 2020; 7:203-209Karacan I, Akgun TK, Agaoglu NB *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478289>
26. **Repurposing Nimesulide, a Potent Inhibitor of the BOAT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.** *SLAS Discov* 2020:2472555220934421Scalise M, Indiveri C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500793>
27. **[Application of Reyaning Mixture in evaluating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:1465-1472Bao L, Shi YJ, Geng ZH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489022>

## Biomarkers - Genetics (83 articles)

1. **Diagnostic Performance of a Rapid Point of Care Test for SARS-CoV-2 in an Urban ED Setting.** *Acad Emerg Med* 2020; McDonald S, Courtney DM, Clark AE *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492760>
2. **Drive-Through COVID-19 Testing During the 2020 Pandemic: a safe, efficient, and scalable model for pediatric patients and healthcare workers.** *Acad. Pediatr.* 2020; Flynn EF, Kuhn E, Shaik M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479895>
3. **ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy.** *Aging (Albany NY)* 2020; 12Asselta R, Paraboschi EM, Mantovani A, Duga S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501810>
4. **Infection with SARS-CoV-2 causes abnormal laboratory results of multiple organs in patients.** *Aging (Albany NY)* 2020; 12Yang AP, Li HM, Tao WQ *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484453>
5. **Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors.** *Allergy* 2020; Radzikowska U, Ding M, Tan G *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496587>
6. **Nasopharyngeal swab collection in the suspicion of Covid-19.** *Am. J. Otolaryngol.* 2020:102551Piras A, Rizzo D, Longoni E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487335>
7. **Expedited SARS-CoV-2 Screening of Donors and Recipients Supports Continued Solid Organ Transplant.** *Am J Transplant* 2020; Lieberman JA, Mays JA, Wells C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476285>



8. **Hematological findings in coronavirus disease 2019: indications of progression of disease.** *Ann. Hematol.* 2020; Liu X, Zhang R, He G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495027>
9. **Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19.** *Biomark. Med.* 2020; Li J, Li M, Zheng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490680>
10. **Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.** *Biomed. Pharmacother.* 2020; 128:110296Ghafouri-Fard S, Noroozi R, Vafaei R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480226>
11. **Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study.** *BMC Med* 2020; 18:168Shi J, Li Y, Zhou X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493370>
12. **Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.** *Cell* 2020; Shen B, Yi X, Sun Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492406>
13. **Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies.** *Clin Chem* 2020; Favresse J, Eucher C, Elsen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484887>
14. **In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.** *Clin Chem* 2020; Jackups R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474583>
15. **Clinical Performance of the Roche SARS-CoV-2 Serologic Assay.** *Clin Chem* 2020; Tang MS, Hock KG, Logsdon NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484860>
16. **Urinalysis parameters for predicting severity in coronavirus disease 2019 (COVID-19).** *Clin Chem Lab Med* 2020; Bonetti G, Manelli F, Bettinardi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484450>
17. **Comparison of the Elecsys(R) Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma.** *Clin Chim Acta* 2020; Egger M, Bundschuh C, Wiesinger K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485155>
18. **ELEVATED MONOCYTE DISTRIBUTION WIDTH IN COVID-19 PATIENTS: THE CONTRIBUTION OF THE NOVEL SEPSIS INDICATOR.** *Clin Chim Acta* 2020; Ognibene A, Lorubbio M, Magliocca P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504637>
19. **Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays?** *Clin Chim Acta* 2020; Plebani M, Padoan A, Negrini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485157>
20. **Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza.** *Clin Infect Dis* 2020; Gu S, Chen Y, Wu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497191>
21. **Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients.** *Clin Infect Dis* 2020; Wang X, Guo X, Xin Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497196>
22. **SARS-CoV-2 serology: Test, test, test, but interpret with caution!** *Clin Med (Lond)* 2020; Bermingham WH, Wilding T, Beck S, Huissoon A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487681>
23. **Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected COVID-19 presenting to the hospital.** *Clin Microbiol Infect* 2020; Ong DSY, de Man SJ, Lindeboom FA, Koeleman JGM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502646>
24. **Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients.** *Clin Microbiol Infect* 2020; Van Elslande J, Houben E, Depypere M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473953>
25. **Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients.** *Crit Care* 2020; 24:290Wu Z, Hu R, Zhang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503680>
26. **Biomarkers associated with COVID-19 disease progression.** *Crit. Rev. Clin. Lab. Sci.* 2020:1-11Ponti G, Maccaferri M, Ruini C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503382>
27. **What Do We Need to Know to Improve Diagnostic Testing Methods for the 2019 Novel Coronavirus?** *Cureus* 2020; 12:e8263Mustafa Z, Ghaffari M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483515>
28. **Novel wastewater surveillance strategy for early detection of coronavirus disease 2019 hotspots.** *Curr Opin Environ Sci Health* 2020; 17:8-13Venugopal A, Ganesan H, Sudalaimuthu Raja SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501429>
29. **Practical Guidelines for Collection, Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens.** *Curr Protoc Cytom* 2020; 93:e77Bain W, Lee JS, Watson AM, Stitt-Fischer MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502333>
30. **Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents.** *Cytometry A* 2020; Reifel KM, Swan BK, Jellison ER *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488957>
31. **Proposed guidelines for screening of hyperglycemia in patients hospitalized with COVID-19 in low resource settings.** *Diabetes Metab Syndr* 2020; 14:753-756Goyal A, Gupta S, Gupta Y, Tandon N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502958>
32. **Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19, Seoul.** *Emerg Infect Dis* 2020; 26Han MS, Seong MW, Kim N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497001>
33. **Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.** *Emerg Microbes Infect* 2020; 9:1123-1130Han H, Ma Q, Li C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475230>
34. **Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.** *Emerg Microbes Infect* 2020; 9:1096-1101Shen L, Wang C, Zhao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476607>
35. **Keys for analysis of diagnostic and serologic tests for CoV-2.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Laccourreye O, Cohen R, Couloigner V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473864>
36. **Authors' response: SARS-CoV-2 detection by real-time RT-PCR.** *Euro Surveill* 2020; 25Corman VM, Drosten C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489177>
37. **Letter to the editor: SARS-CoV-2 detection by real-time RT-PCR.** *Euro Surveill* 2020; 25Pillone T, Scherz V, Jatton K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489175>
38. **No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019.** *Fertil. Steril.* 2020; 113:1135-1139Pan F, Xiao X, Guo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482249>

39. **Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide.** *Hla* 2020; Barquera R, Collen E, Di D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475052>
40. **NLR: A Cost-effective Nomogram to Guide Therapeutic Interventions in COVID-19.** *Immunol. Invest.* 2020;1-9Kerboua KE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482134>
41. **Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.** *In Vivo* 2020; 34:1589-1592Smetana K, Jr., Brabek J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503815>
42. **SARS-CoV-2 Laboratory Testing in India's Pandemic Response: A Public Health Perspective.** *Indian J. Public Health* 2020; 64:S128-s131Moorthy M, Fletcher J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496242>
43. **Unfolding SARS-CoV-2 viral genome to understand its gene expression regulation.** *Infect Genet Evol* 2020:104386Dinka H, Milkesa A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473977>
44. **SARS-CoV-2 molecular and phylogenetic analysis in COVID-19 patients: A preliminary report from Iran.** *Infect Genet Evol* 2020:104387Tabibzadeh A, Zamani F, Laali A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485332>
45. **Universal screening for SARS-CoV-2 in asymptomatic obstetric patients in Tokyo, Japan.** *Int J Gynaecol Obstet* 2020; Ochiai D, Kasuga Y, Iida M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496574>
46. **Fast SARS-CoV-2 detection by RT-qPCR in preheated nasopharyngeal swab samples.** *Int J Infect Dis* 2020; Alcoba-Florez J, Gonzalez-Montelongo R, Inigo-Campos A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492531>
47. **Evaluation of novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples.** *Int J Infect Dis* 2020; Porte L, Legarraga P, Vollrath V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497809>
48. **SARS-CoV-2 Antibody Testing - Questions to be asked.** *J Allergy Clin Immunol* 2020; Ozcurumez MK, Ambrosch A, Frey O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479758>
49. **Clinical Validation of a SARS-CoV-2 Real-Time Reverse Transcription PCR Assay Targeting the Nucleocapsid Gene.** *J Appl Lab Med* 2020; SoRelle JA, Frame I, Falcon A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483586>
50. **Elevated serum aspartate aminotransferase level identifies patients with coronavirus disease 2019 and predicts the length of hospital stay.** *J. Clin. Lab. Anal.* 2020:e23391Gu X, Li X, An X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488888>
51. **Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: A multicenter descriptive study.** *J. Clin. Lab. Anal.* 2020:e23415Shi M, Chen L, Yang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488958>
52. **A Comprehensive Approach Is Vital for Diagnosing COVID-19: A Case of False Negative.** *J. Clin. Med. Res.* 2020; 12:315-319Balla M, Merugu GP, Pokal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489507>
53. **Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies.** *J Clin Virol* 2020; 129:104468Beavis KG, Matushek SM, Abeleda APF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485620>
54. **Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital.** *J Clin Virol* 2020; 129:104472Blairon L, Wilmet A, Beukinga I, Tre-Hardy M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504944>
55. **Rapid implementation and validation of a cold-chain free SARS-CoV-2 diagnostic testing workflow to support surge capacity.** *J Clin Virol* 2020; 128:104469Bosworth A, Whalley C, Poxon C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474371>
56. **Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance.** *J Clin Virol* 2020; 129:104474Degli-Angeli E, Dragavon J, Huang ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504946>
57. **Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study.** *J Clin Virol* 2020; 129:104473Perez-Garcia F, Perez-Tanoira R, Romanyk J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504945>
58. **Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis.** *J Clin Virol* 2020; 129:104455Schoy A, Anantharajah A, Bodeus M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485618>
59. **Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients.** *J Infect* 2020; Tuailon E, Bollore K, Pisoni A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504735>
60. **Decreased B cells on admission was associated with prolonged viral RNA shedding from respiratory tract in Coronavirus Disease 2019: a case control study.** *J Infect Dis* 2020; Hao S, Lian J, Lu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474608>
61. **Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.** *J Intensive Care* 2020; 8:36Huang I, Pranata R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483488>
62. **Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis.** *J Med Virol* 2020; Aikawa T, Takagi H, Ishikawa K, Kuno T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484975>
63. **Potential pitfalls of routine SARS-CoV-2 serology for mass screening.** *J Med Virol* 2020; Belec L, Pere H, Bouassa RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484942>
64. **Evidence for mutations in SARS-CoV-2 Italian isolates potentially affecting virus transmission.** *J Med Virol* 2020; Benvenuto D, Demir AB, Giovanetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492183>
65. **Clearance and Persistence of SARS-CoV-2 RNA in COVID-19 patients.** *J Med Virol* 2020; Carmo A, Pereira-Vaz J, Mota V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484958>
66. **COVID-19 presenting with immune thrombocytopenia: a case report and review of the literature.** *J Med Virol* 2020; Murt A, Eskazan AE, Yilmaz U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497344>
67. **Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in Lung cancer.** *J Med Virol* 2020; Sagkan RI, Akin-Bali DF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492203>
68. **A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.** *J Med Virol*

- 2020; Zhang Z, Wang S, Tu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501538>
69. **Bonuses and pitfalls of a paperless drive-through screening and COVID-19: A field report.** *J Microbiol Immunol Infect* 2020; Lee E, Mohd Esa NY, Wee TM, Soo CI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474025>
  70. **Au-decorated BN nanotube as a breathalyzer for potential medical applications.** *J. Mol. Liq.* 2020; 312:113454Ge C, Li M, Li M, Peyghan AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501315>
  71. **The different tests for the diagnosis of COVID-19 - A review in Brazil so far.** *JBRA Assist Reprod* 2020; Laureano AFS, Riboldi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491306>
  72. **Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.** *JCI Insight* 2020; Zhao Y, Qin L, Zhang P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501293>
  73. **The potential transmission of SARS-CoV-2 from patients with negative RT-PCR swab tests to others: two related clusters of COVID-19 outbreak.** *Jpn. J. Infect. Dis.* 2020; Cao G, Tang S, Yang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475877>
  74. **A Case of COVID-19 Patient with False-negative for SARS-CoV-2 of Pharyngeal Swab, from a Chinese traveller Returning from Wuhan, Hubei Province, China, January 2020.** *Jpn. J. Infect. Dis.* 2020; Ishikane M, Miyazato Y, Kustuna S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475881>
  75. **Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.** *Life Sci* 2020:117905Banu N, Panikar SS, Leal LR, Leal AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504757>
  76. **The role of selectivity of the SARS-CoV-2 virus for human genetic profiles in susceptibility and resistance to COVID-19.** *New Microbes New Infect* 2020; 36:100697Khan FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483490>
  77. **The origin of SARS-CoV-2 in Istanbul: Sequencing findings from the epicenter of the pandemic in Turkey.** *North Clin Istanbul* 2020; 7:203-209Karacan I, Akgun TK, Agaoglu NB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478289>
  78. **Differentiating Between 2019 Novel Coronavirus Pneumonia and Influenza Using a Nonspecific Laboratory Marker-Based Dynamic Nomogram.** *Open Forum Infect Dis* 2020; 7:ofaa169Wang L, Liu Y, Zhang T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490031>
  79. **Oral saliva and COVID-19.** *Oral Oncol* 2020; 108:104821Baghizadeh Fini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474389>
  80. **Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays.** *Protein Expr. Purif.* 2020:105686Esposito D, Mehalko J, Drew M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504802>
  81. **Characteristics and assessment of the usefulness of serological tests in the diagnostic of infections caused by coronavirus SARS-CoV-2 on the basis of available manufacturer's data and literature review.** *Przegl. Epidemiol.* 2020; 74:49-68Rastawicki W, Rokosz-Chudziak N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500987>
  82. **Utility of lateral flow tests in SARS-CoV-2 infection monitorization.** *Rev. Esp. Quimioter.* 2020; Candel FJ, Vinuela-Prieto JM, Gonzalez Del Castillo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492991>
  83. **The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:488Li J, Zhang C, Wu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503657>
  84. **The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.** *Turk J Med Sci* 2020; Goker H, Aladag Karakulak E, Demiroglu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496734>

## Children (25 articles)

1. **Understanding the age divide in COVID-19: Why are children overwhelmingly spared?** *Am J Physiol Lung Cell Mol Physiol* 2020; Lingappan K, Karmouty-Quintana H, Davies J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491949>
2. **The role of pulmonary CT scans for children during the COVID-19 pandemic.** *BMC Med* 2020; 18:171Sinha IP, Kaleem M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498685>
3. **COVID-19, economic impact and child mortality: A global concern.** *Clin. Nutr.* 2020; Kabir M, Saqib MAN, Zaid M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499056>
4. **Global Coronavirus Pandemic (SARS CoV-2): Past, Present, And Future Of Pediatric Dermatology.** *Dermatol Ther* 2020:e13767Simonetti O, Diotallevi F, Campanati A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500648>
5. **Dermatological Manifestation of Pediatrics Multisystem Inflammatory Syndrome Associated with COVID-19 in a 3-Year-Old Girl.** *Dermatol Ther* 2020:e13770Yozgat CY, Uzuner S, Duramaz BB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500647>
6. **Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19, Seoul.** *Emerg Infect Dis* 2020; 26Han MS, Seong MW, Kim N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497001>
7. **Point-of-care lung ultrasound in three neonates with COVID-19.** *Eur. J. Pediatr.* 2020; Gregorio-Hernandez R, Escobar-Izquierdo AB, Cobas-Pazos J, Martinez-Gimeno A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504135>
8. **Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks.** *Eur. J. Pediatr.* 2020; Parri N, Magista AM, Marchetti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495147>
9. **Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review.** *Eur. J. Pediatr.* 2020; Sanna G, Serrau G, Bassareo PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474800>
10. **No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020.** *Euro Surveill* 2020; 25Heavey L, Casey G, Kelly C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489179>
11. **Asymptomatic COVID-19 infection in a child with nasal foreign body.** *Int J Pediatr Otorhinolaryngol* 2020; 135:110092Diercks GR, Park BJ, Myers LB, Kwolek CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496734>



term=32480136

12. **Adolescents' Motivations to Engage in Social Distancing During the COVID-19 Pandemic: Associations With Mental and Social Health.** *J. Adolesc. Health* 2020; Oosterhoff B, Palmer CA, Wilson J, Shook N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487491>
13. **The Unexpected Risks of COVID-19 on Asthma Control in Children.** *J Allergy Clin Immunol Pract* 2020; Oreskovic NM, Kinane TB, Aryee E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497662>
14. **Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of COVID-19.** *J. Am. Acad. Child Adolesc. Psychiatry* 2020; Loades ME, Chatburn E, Higson-Sweeney N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504808>
15. **SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines.** *J Biol Regul Homeost Agents* 2020; 34Ronconi G, Tete G, Kritas SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476380>
16. **Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: A multicenter descriptive study.** *J. Clin. Lab. Anal.* 2020:e23415Shi M, Chen L, Yang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488958>
17. **Characteristics of Hospitalized Pediatric COVID-19 Cases - Chicago, Illinois, March - April 2020.** *J Pediatr Infect Dis Soc* 2020; Mannheim J, Gretsches S, Layden JE, Fricchione MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479632>
18. **The first pediatric patients with coronavirus disease 2019 (COVID-19) in Japan; The risk of co-infection with other respiratory viruses.** *Jpn. J. Infect. Dis.* 2020; Kakuya F, Okubo H, Fujiyasu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475878>
19. **Neonates Hospitalized with Community-Acquired SARS-CoV-2 in a Colorado Neonatal Intensive Care Unit.** *Neonatology* 2020:1-5White A, Mukherjee P, Stremming J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498065>
20. **Pediatric coronavirus disease 2019 (COVID-19): An insight from west of Iran.** *North Clin Istanb* 2020; 7:284-291Soltani J, Sedighi I, Shalchi Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478302>
21. **Clinical Manifestations of Children with COVID-19: a Systematic Review.** *Pediatr Pulmonol* 2020; de Souza TH, Nadal JA, Nogueira RJN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492251>
22. **Overview: The history and pediatric perspectives of severe acute respiratory syndromes: Novel or just like SARS.** *Pediatr Pulmonol* 2020; Hon KL, Leung KKY, Leung AKC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483934>
23. **Paediatric aspects of COVID-19: An update.** *Respir Med Res* 2020; 78:100765Kammoun R, Masmoudi K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504982>
24. **Analysis and suggestions for the preview and triage screening of children with suspected COVID-19 outside the epidemic area of Hubei Province.** *Transl Pediatr* 2020; 9:126-132Zhang N, Deng Y, Li W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32477912>
25. **SARS-CoV-2 infection in infants under 1 year of age in Wuhan City, China.** *World J Pediatr* 2020; Sun D, Chen X, Li H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504360>

## Clinical Features (39 articles)

1. **Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.** *BMJ* 2020; 369:m1985Docherty AB, Harrison EM, Green CA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32444460>
2. **Atypical presentations of coronavirus disease 2019 in a patient with acute obstructive suppurative cholangitis.** *Clin Res Hepatol Gastroenterol* 2020; Zhai LL, Xiang F, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482542>
3. **Superficial thrombophlebitis in a patient with COVID 19: Heparin treatment after evaluation of D - Dimer: COVID 19 and Superficial thrombophlebitis.** *Dermatol Ther* 2020:e13768Demirbas A, Elmas OF, Tursten U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500589>
4. **Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.** *Dermatol Ther* 2020; Valenti M, Facheris P, Pavia G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474988>
5. **Dermatological Manifestation of Pediatrics Multisystem Inflammatory Syndrome Associated with COVID-19 in a 3-Year-Old Girl.** *Dermatol Ther* 2020:e13770Yozgat CY, Uzuner S, Duramaz BB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500647>
6. **Headache is an important symptom in patients with coronavirus disease 2019 (COVID-19).** *Diagnosis (Berl)* 2020; Lippi G, Mattiuzzi C, Bovo C, Henry BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478675>
7. **Parotitis-Like Symptoms Associated with COVID-19, France, March-April 2020.** *Emerg Infect Dis* 2020; 26Lechien JR, Chetrit A, Chekkoury-Idrissi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491984>
8. **Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks.** *Eur. J. Pediatr.* 2020; Parri N, Magista AM, Marchetti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495147>
9. **Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis?** *Eur. Urol.* 2020; Mumm JN, Osterman A, Ruzicka M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475747>
10. **Ocular manifestations of coronavirus disease 2019.** *Graefes Arch Clin Exp Ophthalmol* 2020; Bostanci Ceran B, Ozates S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504100>
11. **Ocular Manifestations of COVID-19 (SARS-CoV-2): A Critical Review of Current Literature.** *In Vivo* 2020; 34:1619-1628Douglas KAA, Douglas VP, Moschos MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503820>
12. **Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms.** *Inflam Res* 2020; Criado PR, Abdalla BMZ, de Assis IC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488318>
13. **Clinical Features and Short-term Outcomes of Elderly Patients With COVID-19.** *Int J Infect Dis* 2020; Li P, Chen L, Liu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492533>
14. **Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study.** *Intern Emerg Med* 2020; Lapostolle F, Schneider E, Vianu I *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474850>
15. **Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries.** *J Am Acad Dermatol* 2020; Freeman EE, McMahon DE, Lipoff JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479979>
  16. **CHILBLAIN-LIKE ACRAL LESIONS DURING THE COVID-19 PANDEMIC ("COVID TOES"): HISTOLOGIC, IMMUNOFLOUORESCENCE AND IMMUNOHISTOCHEMICAL STUDY OF 17 CASES.** *J Am Acad Dermatol* 2020; Kanitakis J, Lesort C, Danset M, Jullien D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502585>
  17. **Reply to: "Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak".** *J Am Acad Dermatol* 2020; Ruggiero G, Arcangeli F, Lotti T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497698>
  18. **High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients.** *J Am Coll Cardiol* 2020; Voicu S, Bonnin P, Stepanian A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479784>
  19. **Burnout and Posttraumatic Stress Disorder in the Coronavirus Disease 2019 (COVID-19) Pandemic: Intersection, Impact, and Interventions.** *J Am Coll Radiol* 2020; Restauri N, Sheridan AD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479798>
  20. **Characteristics of U.S. Nursing Homes with COVID-19 Cases.** *J Am Geriatr Soc* 2020; Abrams HR, Loomer L, Gandhi A, Grabowski DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484912>
  21. **Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: A descriptive study.** *J Clin Virol* 2020; 129:104475 Yang L, Liu J, Zhang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485619>
  22. **SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report.** *J Endocrinol Invest* 2020; Ippolito S, Dentali F, Tanda ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488726>
  23. **Retiform purpura as a dermatological sign of covid-19 coagulopathy.** *J Eur Acad Dermatol Venereol* 2020; Bosch-Amate X, Giavedoni P, Podlipnik S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491234>
  24. **Eosinophilic granulomatosis with polyangiitis mimicking COVID-19: a case report.** *J Eur Acad Dermatol Venereol* 2020; Hashizume H, Sano Y, Furukawa S, Imokawa S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495957>
  25. **No antibody response in acral cutaneous manifestations associated with COVID-19 ?** *J Eur Acad Dermatol Venereol* 2020; Mahieu R, Tillard L, Le Guillou-Guillemette H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488946>
  26. **Clinical and histological characterization of late appearance maculopapular eruptions in association with the coronavirus disease 2019. A case series of seven patients.** *J Eur Acad Dermatol Venereol* 2020; Reymundo A, Fernaldez-Bernaldez A, Reolid A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495368>
  27. **Exanthema and eosinophilia in Covid-19 patients: has viral infection a role in drug induced exanthemas?** *J Eur Acad Dermatol Venereol* 2020; Rosell-Diaz AM, Mateos-Mayo A, Nieto-Benito LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495400>
  28. **SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes.** *J Infect* 2020; Graham N, Junghans C, Downes R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504743>
  29. **Clearance and Persistence of SARS-CoV-2 RNA in COVID-19 patients.** *J Med Virol* 2020; Carmo A, Pereira-Vaz J, Mota V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484958>
  30. **Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of CoViD-19 patient with diarrhea.** *J Med Virol* 2020; Carnevale S, Beretta P, Morbini P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492199>
  31. **Letter to the Editor: A Missing Link between SARS-CoV-2 and the Eye?: ACE2 Expression on the Ocular Surface.** *J Med Virol* 2020; Grajewski RS, Rokohl AC, Becker M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497334>
  32. **COVID-19 presenting with immune thrombocytopenia: a case report and review of the literature.** *J Med Virol* 2020; Murt A, Eskazan AE, Yilmaz U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497344>
  33. **Coronavirus Disease 2019 Presenting as Conjunctivitis.** *Korean J Fam Med* 2020; Ying NY, Idris NS, Muhamad R, Ahmad I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475104>
  34. **Predicting COVID-19 Incidence Using Anosmia and Other COVID-19 Symptomatology: Preliminary Analysis Using Google and Twitter.** *Otolaryngol Head Neck Surg* 2020; 194:599820932128 Panuganti BA, Jafari A, MacDonald B, DeConde AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484425>
  35. **Clinical Manifestations of Children with COVID-19: a Systematic Review.** *Pediatr Pulmonol* 2020; de Souza TH, Nadal JA, Nogueira RJN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492251>
  36. **Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis.** *Rev Med Virol* 2020; e2112 Pormohammad A, Ghorbani S, Khatami A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502331>
  37. **Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan, China.** *Theranostics* 2020; 10:6113-6121 Li L, Yang L, Gui S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483442>
  38. **Descriptive characteristics of hospitalized adult smokers and never-smokers with COVID-19.** *Tab Induc Dis* 2020; 18:46 Kalan ME, Ghobadi H, Taleb ZB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489343>
  39. **Characteristics of the initial patients hospitalized for COVID-19: a single-center report.** *Turk J Med Sci* 2020; Medetalibeyoglu A, Senkal N, Capar G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490641>

## CNS (33 articles)

1. **Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.** *ACS Chem Neurosci* 2020; Yin XX, Zheng XR, Peng W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485101>

2. **Neuroleptic malignant syndrome in patients with COVID-19.** *Am J Emerg Med* 2020; Soh M, Hifumi T, Isokawa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473756>
3. **New onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2.** *Clin Microbiol Infect* 2020; Patel A, Charani E, Ariyanayagam D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502645>
4. **Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy, MRI Brain and Cerebrospinal Fluid Findings: Case 2.** *Cureus* 2020; 12:e7930Espinosa PS, Rizvi Z, Sharma P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499974>
5. **Basal Ganglia Involvement and Altered Mental Status: A Unique Neurological Manifestation of Coronavirus Disease 2019.** *Cureus* 2020; 12:e7869Haddadi K, Ghasemian R, Shafizad M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489724>
6. **COVID-19 Pandemic: A Neurological Perspective.** *Cureus* 2020; 12:e7889Lahiri D, Ardila A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489743>
7. **Anosmia and Ageusia as the Only Indicators of Coronavirus Disease 2019 (COVID-19).** *Cureus* 2020; 12:e7918Zhang Q, Shan KS, Abdollahi S, Nace T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494532>
8. **Headache is an important symptom in patients with coronavirus disease 2019 (COVID-19).** *Diagnosis (Berl)* 2020; Lippi G, Mattiuzzi C, Bovo C, Henry BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478675>
9. **Encephalopathy and Encephalitis Associated with Cerebrospinal Fluid Cytokine Alterations and Coronavirus Disease, Atlanta, Georgia, USA, 2020.** *Emerg Infect Dis* 2020; 26Benamer K, Agarwal A, Auld SC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487282>
10. **Patient-Reported Outcome Questionnaires for the evaluation of olfactory and gustatory dysfunctions in COVID-19.** *Eur Arch Otorhinolaryngol* 2020; Lechien JR, Hsieh J, Barillari MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494948>
11. **Olfactory and gustatory dysfunctions in 100 patients hospitalized for COVID-19: sex differences and recovery time in real-life.** *Eur Arch Otorhinolaryngol* 2020; Meini S, Suardi LR, Busoni M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500326>
12. **A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details.** *Eur J Neurol* 2020; Romoli M, Jelcic I, Bernard-Valnet R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503088>
13. **Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.** *Front Immunol* 2020; 11:1059Mohn N, Pul R, Kleinschnitz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32477373>
14. **Temporary hyposmia in COVID-19 patients.** *HNO* 2020; Bocksberger S, Wagner W, Hummel T *et al.*
15. **Psychophysical olfactory testing in COVID-19: is smell function really impaired in nearly all patients?** *Int Forum Allergy Rhinol* 2020; Marino-Sanchez F, Santamaria A, de Los Santos G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497397>
16. **Cerebrovascular and Neurological Dysfunction under the Threat of COVID-19: Is There a Comorbid Role for Smoking and Vaping?** *Int J Mol Sci* 2020; 21Archie SR, Cucullo L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486196>
17. **Knowledge, Attitudes, Practices, and Burden During the COVID-19 Pandemic in People with Parkinson's Disease in Germany.** *J Clin Med* 2020; 9Zipprich HM, Teschner U, Witte OW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486074>
18. **Potential Neuroinvasive Pathways of SARS-CoV-2: Deciphering the Spectrum of Neurological Deficit Seen in Coronavirus Disease 2019 (COVID-19).** *J Med Virol* 2020; Baig AM, Sanders EC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492193>
19. **First Case of Focal Epilepsy Associated with SARS-Coronavirus-2.** *J Med Virol* 2020; Elgamasy S, Kamel MG, Ghozy S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484990>
20. **COVID-19 in teriflunomide-treated patients with multiple sclerosis.** *J Neurol* 2020; Maghzi AH, Houtchens MK, Preziosa P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494856>
21. **COVID-19-associated acute disseminated encephalomyelitis (ADEM).** *J Neurol* 2020; Parsons T, Banks S, Bae C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474657>
22. **COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion.** *J Neurol Sci* 2020; 415:116941Hayashi M, Sahashi Y, Baba Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474220>
23. **SARS-CoV2 as a potential trigger of neurodegenerative diseases.** *Mov Disord* 2020; Gomez-Pinedo U, Matias-Guiu J, Sanclemente-Alaman I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502296>
24. **SARS-CoV-2 as a trigger of neurodegeneration: thinking ahead.** *Mov Disord* 2020; Outeiro TF, Krisko A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502289>
25. **Guillain-Barre Syndrome in a Patient with Minimal Symptoms of COVID-19 Infection.** *Muscle Nerve* 2020; Oguz-Akarsu E, Ozpar R, Mirzayev H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497292>
26. **Neurologic Features in Severe SARS-CoV-2 Infection.** *N Engl J Med* 2020; Helms J, Kremer S, Merdji H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32294339>
27. **The neurological manifestations of COVID-19: a review article.** *Neurol Sci* 2020; Niazkar HR, Zibae B, Nasimi A, Bahri N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483687>
28. **Predicting COVID-19 Incidence Using Anosmia and Other COVID-19 Symptomatology: Preliminary Analysis Using Google and Twitter.** *Otolaryngol Head Neck Surg* 2020:194599820932128Panuganti BA, Jafari A, MacDonald B, DeConde AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484425>
29. **Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks.** *Pharmacol Res* 2020; 158:104917Boccanegra B, Verhaart IEC, Cappellari O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485610>
30. **Prevention of COVID-19 infection in the medical population: a possible help from anosmia?** *Rev Recent Clin Trials* 2020; Chiarella G, Pizzonato R, Malanga D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493200>
31. **COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System.** *World Neurosurg* 2020; Abboud H, Abboud FZ, Kharbouch H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474093>
32. **COVID-19-associated encephalitis mimicking glial tumor: a case report.** *World Neurosurg* 2020; Efe IE, Aydin OU, Alabulut A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479911>
33. **Letter to the editor: Awake Craniotomy for Intracranial Gliomas during COVID-19 Pandemic.** *World Neurosurg* 2020; Nunez-Velasco S, Mercado-Pimentel R, Rodriguez-Arias R.



## Complications (54 articles)

1. **Dysfunctional Coagulation in COVID-19: From Cell to Bedside.** *Adv Ther* 2020; Wang J, Saguner AM, An J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504450>
2. **COVID-19-RELATED AORTIC THROMBOSIS: A REPORT OF FOUR CASES.** *Ann. Vasc. Surg.* 2020; Gomez-Arbelaez D, Ibarra-Sanchez G, Garcia-Gutierrez A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474145>
3. **Preeclampsia-like syndrome induced by severe COVID-19: a prospective observational study.** *Bjog* 2020; Mendoza M, Garcia-Ruiz I, Maiz N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479682>
4. **Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report.** *Chest* 2020; Moores LK, Tritschler T, Brosnahan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502594>
5. **[Increased risk of deep vein thrombosis in intensive care unit patients with CoVID-19 infections?- Preliminary data].** *Chirurg* 2020; Zerwes S, Hernandez Cancino F, Liebetrau D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504106>
6. **Type 3 hypersensitivity in COVID-19 vasculitis.** *Clin Immunol* 2020:108487Roncati L, Ligabue G, Fabbiani L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479986>
7. **Abrupt deterioration and pulmonary embolism in COVID-19: a case report.** *Clin Med (Lond)* 2020; Motwani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503799>
8. **Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.** *Clin Rheumatol* 2020; Soy M, Keser G, Atagunduz P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474885>
9. **Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study.** *Crit Care* 2020; 24:275Fraisie M, Logre E, Pajot O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487122>
10. **Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series.** *Crit Care* 2020; 24:299Wang J, Yang Q, Zhang P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503617>
11. **Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients.** *Crit Care* 2020; 24:290Wu Z, Hu R, Zhang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503680>
12. **Coronavirus Disease 2019 (COVID-19) Can Masquerade as Acute Postoperative Periprosthetic Joint Infection.** *Cureus* 2020; 12:e7857Kenanidis E, Kakoulidis P, Anagnostis P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483507>
13. **Refractory Acute Respiratory Distress Syndrome Secondary to COVID-19 Successfully Extubated to Average Volume-assured Pressure Support Non-invasive Ventilator.** *Cureus* 2020; 12:e7849Mittal A, Forte M, Leonard R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483500>
14. **The Clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease.** *Dermatol Ther* 2020:e13730Dursun R, Temiz SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475003>
15. **Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment.** *Dermatol Ther* 2020; Magnano M, Balestri R, Bardazzi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475056>
16. **Pression-induced facial ulcers by prone position for COVID-19 mechanical ventilation.** *Dermatol Ther* 2020; Ramondetta A, Ribero S, Costi S, Dapavo P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495445>
17. **Towards individualized and optimized positioning of non-ventilated COVID-19 patients: Putting the affected parts of the lung(s) on top?** *Diabetes Metab.* 2020; Froelich S, Mandonnet E, Julla JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473964>
18. **Possible long-term endocrine-metabolic complications in COVID-19: lesson from the SARS model.** *Endocrine* 2020; Mongioi LM, Barbagallo F, Condorelli RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488837>
19. **Miller-Fisher syndrome after SARS-CoV-2 infection.** *Eur. J. Neurol.* 2020; Reyes-Bueno JA, Garcia-Trujillo L, Urbaneja P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503084>
20. **Prior and novel coronaviruses, Coronavirus Disease 2019 (COVID-19), and human reproduction: what is known?** *Fertil. Steril.* 2020; 113:1140-1149Segars J, Katler Q, McQueen DB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482250>
21. **A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm).** *IDCases* 2020; 21:e00829Chhetri S, Khamis F, Pandak N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483525>
22. **Isolated severe thrombocytopenia in a patient with COVID-19: A case report.** *IDCases* 2020; 21:e00820Sadr S, SeyedAlinaghi S, Ghiasvand F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483524>
23. **A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.** *Infect Dis (Lond)* 2020:1-3Maillart E, Leemans S, Van Noten H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496938>
24. **High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients.** *J Am Coll Cardiol* 2020; Voicu S, Bonnin P, Stepanian A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479784>
25. **SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines.** *J Biol Regul Homeost Agents* 2020; 34Ronconi G, Tete G, Kritas SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476380>
26. **Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: A multicenter descriptive study.** *J. Clin. Lab. Anal.* 2020:e23415Shi M, Chen L, Yang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488958>
27. **COVID-19 Related Coagulopathy: A Distinct Entity?** *J Clin Med* 2020; 9Marchandot B, Sattler L, Jesel L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486469>
28. **The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis.** *J Infect* 2020; Liu M, Gao Y, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502509>



29. **Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19.** *J Infect* 2020; Nguyen Y, Corre F, Honsel V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474039>
30. **Spontaneous pneumothorax and subcutaneous emphysema in COVID-19 patient: Case report.** *J Infect Public Health* 2020; Ucpinar BA, Sahin C, Yanc U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475804>
31. **Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.** *J Intensive Care* 2020; 8:36Huang I, Pranata R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483488>
32. **COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.** *J. Interv. Card. Electrophysiol.* 2020; Gopinathannair R, Merchant FM, Lakkireddy DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494896>
33. **COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620931239Davoodi L, Jafarpour H, Taghavi M, Razavi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493073>
34. **The Burden of Disease due to COVID-19 in Korea Using Disability-Adjusted Life Years.** *J Korean Med Sci* 2020; 35:e199Jo MW, Go DS, Kim R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476305>
35. **Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence.** *J Med Virol* 2020; Bruno G, Fabrizio C, Santoro CR, Buccoliero GB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497298>
36. **Influenza and COVID-19 Co-infection: Report of 6 cases and review of the Literature.** *J Med Virol* 2020; Ozaras R, Cirpin R, Duran A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497283>
37. **Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?** *J Microbiol Immunol Infect* 2020; Lai CC, Wang CY, Hsueh PR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482366>
38. **COVID-19 update: Covid-19-associated coagulopathy.** *J. Thromb. Thrombolysis* 2020; Becker RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32415579>
39. **Acute pulmonary embolism in COVID-19 related hypercoagulability.** *J. Thromb. Thrombolysis* 2020; Lorenzo C, Francesca B, Francesco P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474757>
40. **Pulmonary embolism response teams in the challenging era of venous thromboembolism associated with COVID-19.** *J Vasc Surg Venous Lymphat Disord* 2020; Porres-Aguilar M, Ayala A, Mukherjee D, Tapon VF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497628>
41. **Reply to "Coronaviruses and immunosuppressed patients. The facts during the third epidemic".** *Liver Transpl.* 2020; Merli M, Perricone G, Lauterio A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475054>
42. **Covid-19 and lung cancer: A greater fatality rate?** *Lung Cancer* 2020; 146:19-22Rogado J, Pangua C, Serrano-Montero G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32505076>
43. **Thromboinflammatory response in SARS-CoV-2 sepsis.** *Med. Leg. J.* 2020:25817220926915Maiese A, Passaro G, Matteis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490726>
44. **Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.** *N Engl J Med* 2020; Ackermann M, Verleden SE, Kuehnel M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32437596>
45. **COVID-19: the vasculature unleashed.** *Nat. Rev. Immunol.* 2020; Teuwen LA, Geldhof V, Pasut A, Carmeliet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32439870>
46. **The role of selectivity of the SARS-CoV-2 virus for human genetic profiles in susceptibility and resistance to COVID-19.** *New Microbes New Infect* 2020; 36:100697Khan FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483490>
47. **SARS-CoV2 RNA detection in a pancreatic pseudocyst sample.** *Pancreatology* 2020; Schepis T, Larghi A, Papa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498972>
48. **Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study.** *Pharmacol. Res.* 2020:104965Russo V, Di Maio M, Attena E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474087>
49. **Venous thromboembolism and COVID-19.** *Respir Med Res* 2020; 78:100759Bertoletti L, Couturaud F, Montani D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474397>
50. **Thrombosis risk associated with COVID-19 infection. A scoping review.** *Thromb Res* 2020; 192:152-160Al-Ani F, Chehade S, Lazo-Langner A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485418>
51. **Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom.** *Thromb Res* 2020; 193:1-4Desborough MJR, Doyle AJ, Griffiths A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485437>
52. **Descriptive characteristics of hospitalized adult smokers and never-smokers with COVID-19.** *Tob Induc Dis* 2020; 18:46Kalan ME, Ghobadi H, Taleb ZB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489343>
53. **Outcome of COVID-19 in Liver Transplant Recipients: a Preliminary Report from Northwestern Italy.** *Transpl Infect Dis* 2020:e13353Patrono D, Lupo F, Canta F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500942>
54. **Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).** *Vasa* 2020:1-5Linnemann B, Bauersachs R, Grebe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501145>

## Cured – Recovered (3 articles)

1. **Miller-Fisher syndrome after SARS-CoV-2 infection.** *Eur. J. Neurol.* 2020; Reyes-Bueno JA, Garcia-Trujillo L, Urbaneja P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503084>
2. **The issue of recurrently positive patients who recovered from COVID-19 according to the current discharge criteria: investigation of patients from multiple medical institutions in Wuhan, China.** *J Infect Dis* 2020; Zou Y, Wang BR, Sun L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491178>
3. **A More Excellent Way: Recovering Mystery in COVID Care.** *J Relig Health* 2020; Genig JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474836>

## Cardiovascular disease (38 articles)

1. **Lifestyle at Time of COVID-19: How Could Quarantine Affect Cardiovascular Risk.** *Am. J. Lifestyle Med.* 2020; 14:240-242Mattioli AV, Ballerini Puviani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32477021>
2. **The Next Wave of Health Care Strain Related to COVID-19: Heart Failure Patients Coming Back in Force: We Must Not Fail Them.** *Can J Cardiol* 2020; Moayed Y, Alba AC, Lee DS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504660>
3. **Coronavirus Disease 2019 With Acute Respiratory Distress Syndrome Mimicking Heart Failure Exacerbation: Time to Rethink.** *Cardiol Res* 2020; 11:196-199Sattar Y, Connerney M, Ullah W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494330>
4. **Coronavirus disease 2019 (COVID-19) and simultaneous acute anteroseptal and inferior ST-segment elevation myocardial infarction.** *Cardiovasc. J. Afr.* 2020; 31:1-4Yolcu M, Gunesdogdu F, Bektas M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490506>
5. **Transcatheter mitral valve repair with MitraClip for severe mitral regurgitation and cardiogenic shock during the COVID-19 pandemic.** *Cardiovasc. Revasc. Med.* 2020; Chitturi KR, Faza NN, Little SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473912>
6. **Approach to Acute Cardiovascular Complications in COVID-19 Infection.** *Circ Heart Fail* 2020; Ranard LS, Fried JA, Abdalla M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500721>
7. **Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19.** *Circulation* 2020; Mazzanti A, Briani M, Kukavica D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501756>
8. **Prevalence of COVID-19 in Out-of-Hospital Cardiac Arrest: Implications for Bystander CPR.** *Circulation* 2020; Sayre MR, Barnard LM, Counts CR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496811>
9. **31 days of COVID-19-cardiac events during restriction of public life-a comparative study.** *Clin Res Cardiol* 2020; Rattka M, Baumhardt M, Dreyhaupt J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494921>
10. **Capacity changes in German certified chest pain units during COVID-19 outbreak response.** *Clin Res Cardiol* 2020; Settellemeier S, Rassaf T, Giannitsis E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476041>
11. **Novel Coronavirus Disease 2019 and Subarachnoid Hemorrhage: A Case Report.** *Cureus* 2020; 12:e7846Craen A, Logan G, Ganti L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483497>
12. **Renin-Angiotensin-System (RAS) and COVID-19 - On the Prescription of RAS Blockers.** *Deutsche Medizinische Wochenschrift* 2020; 145:682-686Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F.
13. **Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).** *Eur Heart J* 2020; Anker SD, Butler J, Khan MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498081>
14. **Facilitating transcatheter aortic valve implantation in the era of COVID-19: Recommendations for programmes.** *Eur. J. Cardiovasc. Nurs.* 2020:1474515120934057Lauck S, Forman J, Borregaard B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498556>
15. **Stroke care during the Covid-19 pandemic: Experience from three large European countries.** *Eur. J. Neurol.* 2020; Bersano A, Kraemer M, Touze E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492764>
16. **Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review.** *Eur. J. Pediatr.* 2020; Sanna G, Serrau G, Bassareo PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474800>
17. **World Heart Federation Briefing on Prevention: Coronavirus Disease 2019 (COVID-19) in Low-Income Countries.** *Glob Heart* 2020; 15:31Thienemann F, Pinto F, Grobbee DE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489804>
18. **Rural and Remote Cardiology During the COVID-19 Pandemic: Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.** *Heart Lung Circ.* 2020; Arnold RH, Tideman PA, Devlin GP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487432>
19. **Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement from the Cardiac Society of Australia and New Zealand (CSANZ).** *Heart Lung Circ.* 2020; Nicholls SJ, Nelson M, Astley C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473781>
20. **Comparative impacts of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality.** *Hypertension* 2020; Zhou F, Liu YM, Xie J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493070>
21. **Response to the letter, "The cardiovascular burden of congenital heart disease - not only in times of COVID-19".** *Int J Cardiol* 2020; Tan W, Aboulhosn J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473922>
22. **Cerebrovascular and Neurological Dysfunction under the Threat of COVID-19: Is There a Comorbid Role for Smoking and Vaping?** *Int J Mol Sci* 2020; 21 Archie SR, Cucullo L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486196>
23. **Bedside Focused Cardiac Ultrasound in COVID-19 from the Wuhan Epicenter: The Role of Cardiac Point-of-Care Ultrasound, Limited Transthoracic Echocardiography, and Critical Care Echocardiography.** *J. Am. Soc. Echocardiogr.* 2020; 33:676-682Zhang L, Wang B, Zhou J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503706>
24. **Acute complicated type B aortic dissection during the New York City COVID-19 surge.** *J. Card. Surg.* 2020; Ikeda S, Shih M, Rhee RY, Youdelman BA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497341>
25. **The great pandemic of 2020: A defining moment for Heart Rhythm Societies and their members.** *J Cardiovasc Electrophysiol* 2020; Lemery R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478882>
26. **Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.** *J Cardiovasc Electrophysiol* 2020; Maraj I, Hummel JP, Taoutel R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485061>
27. **Cardiac arrest during emergency intubation in an elderly patient with confirmed coronavirus disease 2019.** *J. Clin. Anesth.* 2020; 66:109951Tao KM, Hu Y, Zhu XF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504963>
28. **Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties.** *J Clin Med* 2020; 9Schivone M, Gobbi C, Biondi-Zoccai G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498230>
29. **COVID-19: Considerations of Diabetes and Cardiovascular Disease Management.** *J. Diabetes Sci. Technol.* 2020:1932296820930025Ceriello A, Schnell O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498230>

- term=32475168
30. **COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no influence on the clinical severity and outcome.** *J Infect* 2020; Hu J, Zhang X, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474032>
  31. **Estimation of RAAS-Inhibitor effect on the COVID-19 outcome: A Meta-analysis.** *J Infect* 2020; Pirola CJ, Sookoian S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474043>
  32. **COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.** *J Interv. Card. Electrophysiol.* 2020; Gopinathannair R, Merchant FM, Lakkireddy DR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494896>
  33. **COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620931239 Davoodi L, Jafarpour H, Taghavi M, Razavi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493073>
  34. **Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis.** *J Med Virol* 2020; Aikawa T, Takagi H, Ishikawa K, Kuno T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484975>
  35. **Stroke as a complication and prognostic factor of COVID-19.** *Neurologia* 2020; Trejo-Gabriel-Galan JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493597>
  36. **Angiotensin converting enzyme 2 (ACE2) and COVID-19: using antihypertensive medications, pharmacogenetic considerations.** *Pharmacogenomics* 2020; Snyder EM, Johnson BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501190>
  37. **Ischemic Stroke Epidemiology During the COVID-19 Pandemic: Navigating Uncharted Waters With Changing Tides.** *Stroke* 2020:Strokeaha120030791 Tsvigoulis G, Katsanos AH, Ornello R, Sacco S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496937>
  38. **Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic.** *Trends Cardiovasc. Med.* 2020; Ganatra S, Dani SS, Shah S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474135>

## Diagnosis (4 articles)

1. **Generalized Z-numbers with hesitant fuzzy linguistic information and its application to medicine selection for the patients with mild symptoms of the COVID-19.** *Comput Ind Eng* 2020; 145:106517 Ren Z, Liao H, Liu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501363>
2. **Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.** *Eur Heart J* 2020; Gao C, Cai Y, Zhang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498076>
3. **Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).** *J. Biomed. Sci.* 2020; 27:72 Chang FY, Chen HC, Chen PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498686>
4. **A Comprehensive Approach Is Vital for Diagnosing COVID-19: A Case of False Negative.** *J. Clin. Med. Res.* 2020; 12:315-319 Balla M, Merugu GP, Pokal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489507>

## DM -MS-Obesity (20 articles)

1. **Related molecular mechanisms of COVID-19, hypertension, and diabetes.** *Am J Physiol Endocrinol Metab* 2020; 318:E881 Akkus E, Sahin M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479159>
2. **Diabetes und Covid-19.** *Diabetes Aktuell* 2020; 18:85 Bergmann A, Schwarz PEH.
3. **Challenges of diabetes care management in developing countries with a high incidence of COVID-19: A brief report.** *Diabetes Metab Syndr* 2020; 14:731-732 Nouhjah S, Jahanfar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473905>
4. **Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?** *Diabetes Metab Syndr* 2020; 14:725-727 Singh AK, Singh R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473903>
5. **Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 infection.** *Diabetes Obes. Metab.* 2020; Wu J, Zhang J, Sun X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496012>
6. **The Australian response to the COVID-19 pandemic and diabetes - lessons learned.** *Diabetes Res Clin Pract* 2020:108246 Andrikopoulos S, Johnson G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502693>
7. **Recommendations for management of diabetic foot ulcers during COVID-19 outbreak.** *Int. Wound J.* 2020; Kelahmetoglu O, Camli MF, Kirazoglu A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501604>
8. **Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico.** *J. Clin. Endocrinol. Metab.* 2020; Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474598>
9. **A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic.** *J. Clin. Endocrinol. Metab.* 2020; Korytkowski M, Antinori-Lent K, Drincic A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498085>
10. **COVID-19: Considerations of Diabetes and Cardiovascular Disease Management.** *J. Diabetes Sci. Technol.* 2020:1932296820930025 Ceriello A, Schnell O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475168>
11. **COVID-19 Awakens a New Focus on Surge Capacity Blood Glucose Testing and the Critical Role of Telehealth in Self-Management.** *J. Diabetes Sci. Technol.* 2020:1932296820930035 Fantz CR, Rivers M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486964>
12. **COVID-19 and Diabetes: Could Diabetes Technology Research Help Pave the Way for Remote Healthcare?** *J. Diabetes Sci. Technol.* 2020:1932296820929714 Fuchs J, Hovorka R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475169>
13. **Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?** *J. Diabetes Sci. Technol.* 2020:1932296820932155 Koufakis T, Metallidis S, Zebekakis P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486846>



14. **New Paradigms in Diabetes Management From the Epicenter.** *J. Diabetes Sci. Technol.* 2020:1932296820930040Levy CJ, Levister CM, Shah NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486856>
15. **Covid-19 and Diabetes in Hawaii.** *J. Diabetes Sci. Technol.* 2020:1932296820931127Melish JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486844>
16. **Battlefield Endocrinology.** *J. Diabetes Sci. Technol.* 2020:1932296820930275Sadhu AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486842>
17. **COVID-19: The Underestimated Pandemic Impacting People With Diabetes.** *J. Diabetes Sci. Technol.* 2020:1932296820929389Shearer D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486884>
18. **COVID-19 Pandemic Triggers Telemedicine Regulation and Intensifies Diabetes Management Technology Adoption in Brazil.** *J. Diabetes Sci. Technol.* 2020:1932296820930033Teles M, Sacchetta T, Matsumoto Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482098>
19. **COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?** *J. Endocrinol. Invest.* 2020; Filardi T, Morano S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495299>
20. **COVID-19: a lever for the recognition of obesity as a disease? The French experience.** *Obesity (Silver Spring)* 2020; Clement K, Coupaye M, Laville M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495493>

## Education and training and science (25 articles)

1. **POPCoRN One-Pagers: Educational Materials for Pediatric Providers Caring For Adults.** *Acad. Pediatr.* 2020; Lang A, Burger B, Doraiswamy V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473879>
2. **Service-learning in response to the coronavirus disease 2019 pandemic: Emerging lessons from the Department of Family Medicine and Public Health at the University of Botswana.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3Tsuma BM, Masupe T, Setlhare V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501020>
3. **COVID-19 Disruption in Cardiothoracic Surgical Training: An Opportunity to Enhance Education.** *Ann Thorac Surg* 2020; Fuller S, Vaporciyan A, Dearani JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497642>
4. **Contributions of dermatologists to COVID-19 research: a brief systematic review.** *Dermatol Ther* 2020:e13713Wang Y, Fang R, Zhang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475035>
5. **Racism In My Medical Education.** *Health Aff (Millwood)* 2020; 39:1087-1091Ko M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479239>
6. **Amplifying the role of knowledge translation platforms in the COVID-19 pandemic response.** *Health Res. Policy Syst.* 2020; 18:58El-Jardali F, Bou-Karroum L, Fadlallah R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493339>
7. **[Nursing Education Strategies During the COVID-19 Epidemic].** *Hu Li Za Zhi* 2020; 67:96-101Hsieh HY, Hsu YY, Ko NY, Yen M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495335>
8. **Medical and Surgical Education Challenges and Innovations in the COVID-19 Era: A Systematic Review.** *In Vivo* 2020; 34:1603-1611Dedeilia A, Sotiropoulos MG, Hanrahan JG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503818>
9. **Coronavirus Disease (COVID-19): A Machine Learning Bibliometric Analysis.** *In Vivo* 2020; 34:1613-1617F DEF, Polimeni A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503819>
10. **Considerations for Underrepresented in Medicine Dermatology Residency Applicants Amidst the COVID-19 Pandemic.** *J Am Acad Dermatol* 2020; Jones VA, Clark KA, Patel PM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504722>
11. **Strategic Deployment of Cardiology Fellows-in-Training Using the Accreditation Council for Graduate Medical Education COVID-19 Framework.** *J Am Heart Assoc* 2020:e017443Gallagher MJ, Bloomington R, Berman AD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476547>
12. **The future of business education: A commentary in the shadow of the Covid-19 pandemic.** *J Bus Res* 2020; 117:1-5Krishnamurthy S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501309>
13. **Medical education in the COVID-19 era: Impact on anesthesiology trainees.** *J. Clin. Anesth.* 2020; 66:109949Anwar A, Seger C, Tollefson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504968>
14. **Disruptions during a pandemic: Gaps identified and lessons learned.** *J. Dent. Educ.* 2020; Elangovan S, Mahrous A, Marchini L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500586>
15. **SARS-CoV-2 Human Challenge Trials: Too Risky, Too Soon.** *J Infect Dis* 2020; Dawson L, Earl J, Livezey J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496536>
16. **Impact of COVID-19 pandemic on medical postgraduate training in the United States.** *Med. Educ. Online* 2020; 25:1774318Edigin E, Eseaton PO, Shaka H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493181>
17. **Peer teaching medical students during a pandemic.** *Med. Educ. Online* 2020; 25:1772014Roberts V, Malone K, Moore P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493174>
18. **Rapid publishing in the era of coronavirus disease 2019 (COVID-19).** *Med. J. Aust.* 2020; Lee AY, Lin MW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474929>
19. **Rapid publishing in the era of coronavirus disease 2019 (COVID-19).** *Med. J. Aust.* 2020; Talley NJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474933>
20. **COVID-19: Are Spanish medicine and nursing students prepared?** *Nurse Educ. Today* 2020; 92:104473Cervera-Gasch A, Gonzalez-Chorda VM, Mena-Tudela D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497867>
21. **Nursing education in a pandemic: Academic challenges in response to COVID-19.** *Nurse Educ. Today* 2020; 92:104471Dewart G, Corcoran L, Thirsk L, Petrovic K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502723>
22. **Effect of Implementing Simulation Education on Health Care Worker Comfort With Nasopharyngeal Swabbing for COVID-19.** *Otolaryngol Head Neck Surg* 2020:194599820933168Mark ME, LoSavio P, Husain I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482155>
23. **Impact of the COVID-19 Pandemic on the Urology Residency Match in Singapore.** *Urology* 2020; Tan YQ, Pek XWG, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504688>



24. **The Good, the Bad, and the Ugly of the COVID-19 Pandemic in a Urology Residency Program in Singapore.** *Urology* 2020; Tan YQ, Wang Z, Tiong HY, Chiong E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473937>
25. **Challenges to Neurosurgical Residency Training during COVID-19 Pandemic: An Indian Perspective.** *World Neurosurg* 2020; Ruparelia J, Gosal JS, Garg M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474090>

## Elderly (15 articles)

1. **Comparison of clinical characteristics and outcomes of patients with coronavirus disease 2019 at different ages.** *Aging (Albany NY)* 2020; 12Zhao M, Wang M, Zhang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499448>
2. **Clinical Features and Short-term Outcomes of Elderly Patients With COVID-19.** *Int J Infect Dis* 2020; Li P, Chen L, Liu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492533>
3. **Mental health of older adults during the COVID-19 pandemic: lessons from history to guide our future.** *Int. Psychogeriatr.* 2020:1-4Chong TWH, Curran E, Ames D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489166>
4. **Local Government Efforts to Mitigate the Novel Coronavirus Pandemic among Older Adults.** *J Aging Soc Policy* 2020:1-11Angel JL, Mudrazija S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501753>
5. **"We are Alone in This Battle": A Framework for a Coordinated Response to COVID-19 in Nursing Homes.** *J Aging Soc Policy* 2020:1-7Behrens LL, Naylor MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497467>
6. **Six Propositions against Ageism in the COVID-19 Pandemic.** *J Aging Soc Policy* 2020:1-11Ehni HJ, Wahl HW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491963>
7. **The Unique Impact of COVID-19 on Older Adults in Rural Areas.** *J Aging Soc Policy* 2020:1-7Henning-Smith C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475255>
8. **COVID-19 and Long-Term Care Policy for Older People in Hong Kong.** *J Aging Soc Policy* 2020:1-7Lum T, Shi C, Wong G, Wong K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476597>
9. **Meeting the Transitional Care Needs of Older Adults with COVID-19.** *J Aging Soc Policy* 2020:1-9Naylor MD, Hirschman KB, McCauley K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476586>
10. **Effectively Engaging Geriatric Patients via Tele dermatology.** *J Am Acad Dermatol* 2020; Simpson CL, Kovarik CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497703>
11. **COVID-19 Pandemic: Workforce Implications for Gerontological Social Work.** *J Gerontol Soc Work* 2020:1-6Berg-Weger M, Schroepfer T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501174>
12. **Older Workers in the Time of COVID-19: The Senior Community Service Employment Program and Implications for Social Work.** *J Gerontol Soc Work* 2020:1-12Halvorsen CJ, Yulikova O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501142>
13. **Geriatric Health in Bangladesh during COVID-19: Challenges and Recommendations.** *J Gerontol Soc Work* 2020:1-4Hossain MM, Mazumder H, Tasnim S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501147>
14. **SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes.** *J Infect* 2020; Graham N, Junghans C, Downes R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504743>
15. **Epidemiological Evidence for Association between Higher Influenza Vaccine Uptake in the Elderly and Lower COVID-19 Deaths in Italy.** *J Med Virol* 2020; Marin-Hernandez D, Schwartz RE, Nixon DF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497290>

## Epidemiology (126 articles)

1. **Leveraging investments in Ebola preparedness for COVID-19 in Sub-Saharan Africa.** *AAS Open Res* 2020; 3:3Ayebare R, Waitt P, Okello S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500116>
2. **Drive-Through COVID-19 Testing During the 2020 Pandemic: a safe, efficient, and scalable model for pediatric patients and healthcare workers.** *Acad. Pediatr.* 2020; Flynn EF, Kuhn E, Shaik M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479895>
3. **[How Acta Medica Portuguesa Adjusted to Pandemic Times].** *Acta Med Port* 2020; 33:357-358Villanueva T, Donato H, Escada P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504509>
4. **Community-based screening and testing for Coronavirus in Cape Town, South Africa: Short report.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3David N, Mash R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501021>
5. **COVID-19 in India: Are Biological and Environmental Factors Helping to Stem the Incidence and Severity?** *Aging Dis* 2020; 11:480-488Chakrabarti SS, Kaur U, Banerjee A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489695>
6. **Novel Coronavirus Disease and the Current Scenario of the Global Health Emergency.** *Antiinflamm. Antiallergy Agents Med. Chem.* 2020; Baruah G, Sahu J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479247>
7. **Population vulnerability to COVID-19 in Europe: a burden of disease analysis.** *Arch Public Health* 2020; 78:47Wyper GMA, Assuncao R, Cuschieri S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501409>
8. **COVID-19-A Novel Zoonotic Disease: A Review of the Disease, the Virus, and Public Health Measures.** *Asia Pac. J. Public Health* 2020:1010539520931326Mackenzie JS, Smith DW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475144>
9. **Heterogenous COVID-19 transmission dynamics within Singapore: a clearer picture of future national responses.** *BMC Med* 2020; 18:164Bagdasarian N, Fisher D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493311>
10. **Real-time monitoring the transmission potential of COVID-19 in Singapore, March 2020.** *BMC Med* 2020; 18:166Tariq A, Lee Y, Roosa K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493466>

11. **COVID-19 pandemic: a viewpoint from Asia.** *Bull Natl Res Cent* 2020; 44:80Abdullah-Al-Shafi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501384>
12. **Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients.** *Cell* 2020; Bost P, Giladi A, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479746>
13. **Forecast and evaluation of COVID-19 spreading in USA with reduced-space Gaussian process regression.** *Chaos Solitons Fractals* 2020; 136:109924Arias Velasquez RM, Mejia Lara JV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501372>
14. **Modelling the spread of COVID-19 with new fractal-fractional operators: Can the lockdown save mankind before vaccination?** *Chaos Solitons Fractals* 2020; 136:109860Atangana A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501371>
15. **A multi-group SEIRA model for the spread of COVID-19 among heterogeneous populations.** *Chaos Solitons Fractals* 2020; 136:109925Contreras S, Villavicencio HA, Medina-Ortiz D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501373>
16. **COVID-19 created chaos across the globe: Three novel quarantine epidemic models.** *Chaos Solitons Fractals* 2020; 138:109928Mishra BK, Keshri AK, Rao YS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501378>
17. **Estimation of COVID-19 dynamics "on a back-of-envelope": Does the simplest SIR model provide quantitative parameters and predictions?** *Chaos Solitons Fractals* 2020; 135:109841Postnikov EB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501369>
18. **Short-term forecasting COVID-19 cumulative confirmed cases: Perspectives for Brazil.** *Chaos Solitons Fractals* 2020; 135:109853Ribeiro M, da Silva RG, Mariani VC, Coelho LDS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501370>
19. **Lessons from being challenged by COVID-19.** *Chaos Solitons Fractals* 2020; 137:109923Tagliazucchi E, Balenzuela P, Travizano M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501375>
20. **Statistical analysis of forecasting COVID-19 for upcoming month in Pakistan.** *Chaos Solitons Fractals* 2020; 138:109926Yousaf M, Zahir S, Riaz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501377>
21. **SARS-CoV-2/COVID-19 and physical distancing: risk for circadian rhythm dysregulation, advice to alleviate it, and natural experiment research opportunities.** *Chronobiol. Int.* 2020;1-4Erren TC, Lewis P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498625>
22. **Emerging study on the transmission of the Novel Coronavirus (COVID-19) from urban perspective: Evidence from China.** *Cities* 2020; 103:102759Liu L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501355>
23. **COVID-19 pandemic: Impact caused by school closure and national lockdown on pediatric visits and admissions for viral and non-viral infections, a time series analysis.** *Clin Infect Dis* 2020; Angoulvant F, Ouldali N, Yang DD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492117>
24. **The natural history and transmission potential of asymptomatic SARS-CoV-2 infection.** *Clin Infect Dis* 2020; Chau NVV, Thanh Lam V, Thanh Dung N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497212>
25. **From Easing Lockdowns to Scaling-Up Community-Based COVID-19 Screening, Testing, and Contact Tracing in Africa - Shared Approaches, Innovations, and Challenges to Minimize Morbidity and Mortality.** *Clin Infect Dis* 2020; Nachega JB, Grimwood A, Mahomed H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474594>
26. **COVID-19 outbreaks in U.S. immigrant detention centers: the urgent need to adopt CDC guidelines for prevention and evaluation.** *Clin Infect Dis* 2020; Openshaw JJ, Travassos MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474574>
27. **Monitoring COVID-19 through Trends in Influenza-like Illness and Laboratory-confirmed Influenza and COVID-19 - New York State, excluding New York City, January 1 - April 12, 2020.** *Clin Infect Dis* 2020; Rosenberg ES, Hall EW, Rosenthal EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474578>
28. **COVID-19 Outbreak Response for an Emergency Department Using In Situ Simulation.** *Cureus* 2020; 12:e7876Jee M, Khamoudes D, Brennan A, O'Donnell J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489730>
29. **Novel wastewater surveillance strategy for early detection of coronavirus disease 2019 hotspots.** *Curr Opin Environ Sci Health* 2020; 17:8-13Venugopal A, Ganesan H, Sudalaimuthu Raja SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501429>
30. **The global impact of the coronavirus pandemic.** *Cytokine Growth Factor Rev.* 2020; Hiscott J, Alexandridi M, Muscolini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487439>
31. **Epidemiology and control of COVID-19.** *Deutsche Medizinische Wochenschrift* 2020; 145:670-674Müller O, Neuhann F, Razum O.
32. **COVID-19-Response - Strategies of the Task-Force Coronavirus and experiences upon implementation in the management of 115 cases at the University Medical Center Freiburg.** *Deutsche Medizinische Wochenschrift* 2020; 145:657-664Rieg S, Busch HJ, Hans F *et al.*
33. **Emergency Medicine's COVID Future: facing the triple challenge after flattening the curve.** *Emerg. Med. Australas.* 2020; Staib A, Small N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484307>
34. **COVID-19, internists and resilience: the north-south Italy outbreak.** *Eur. J. Clin. Invest.* 2020:e13299Di Ciaula A, Palmieri VO, Migliore G, Portincasa P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480424>
35. **Adaptation to SARS-CoV-2 under stress: Role of distorted information.** *Eur. J. Clin. Invest.* 2020:e13294Sharov KS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474908>
36. **The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic.** *Eur J Heart Fail* 2020; Bromage DI, Cannata A, Rind IA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478951>
37. **Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020.** *Euro Surveill* 2020; 25Augustin M, Schommers P, Suarez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489176>
38. **No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020.** *Euro Surveill* 2020; 25Heavey L, Casey G, Kelly C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489179>
39. **Czech Republic and low COVID-19 mortality in the heart of Europe: possible explanations.** *European Heart Journal* 2020; Celko AM, Benes J, Widimsky P.
40. **Linking key intervention timings to rapid declining effective reproduction number to quantify lessons against COVID-19.** *Front Med* 2020; Peng Z, Song W, Ding Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495288>

41. **In the shadow of HIV & TB: A commentary on the COVID epidemic in South Africa.** Glob Public Health 2020;1-13Bulled N, Singer M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486906>
42. **Incarceration And Its Disseminations: COVID-19 Pandemic Lessons From Chicago's Cook County Jail.** Health Aff (Millwood) 2020;101377h1thaff202000652Reinhart E, Chen D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496864>
43. **Are We Ready For The Next Pandemic?** Health Aff (Millwood) 2020; 39:1104Torbay R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479216>
44. **The crucible of COVID-19: what the pandemic is teaching us about health research systems.** Health Res. Policy Syst. 2020; 18:52Turner T, El-Jardali F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487103>
45. **Analysis of Outbreak and Global Impacts of the COVID-19.** Healthcare (Base) 2020; 8Priyadarshini I, Mohanty P, Kumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485875>
46. **[The War Against the Coronavirus Disease (COVID-2019): Keys to Successfully Defending Taiwan].** Hu Li Za Zhi 2020; 67:75-83Huang WT, Chen YY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495332>
47. **[Nurses: A Voice to Lead, Nursing the World to Health-Viewing COVID-19 Epidemic Prevention Efforts in Light of Nightingale's Perspective on Infection Control].** Hu Li Za Zhi 2020; 67:102-110Peng MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495336>
48. **Novel Coronavirus disease 2019 (COVID-19): new challenges and new responsibilities in developing countries.** Hum Vaccin Immunother 2020;1-3Anjum FR, Anam S, Rahman SU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501130>
49. **Lockdown During COVID-19: The Greek Success.** In Vivo 2020; 34:1695-1699Moris D, Schizas D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503831>
50. **A cluster of SARS-CoV-2 infection among Italian tourists visiting India, March 2020.** Indian J Med Res 2020; Vivian Thangaraj JW, Murhekar M, Mehta Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474558>
51. **Impact of lockdown following COVID-19 on the gaming behavior of college students.** Indian J. Public Health 2020; 64:S172-s176Balhara YPS, Kattula D, Singh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496250>
52. **The armed forces medical services response to COVID-19.** Indian J. Public Health 2020; 64:S94-s95Banerji A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496233>
53. **Distribution and growth rate of COVID-19 outbreak in Tamil Nadu: A log-linear regression approach.** Indian J. Public Health 2020; 64:S188-s191Bhaskar A, Ponnuraja C, Srinivasan R, Padmanaban S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496253>
54. **Community preparedness for COVID-19 and frontline health workers in Chhattisgarh.** Indian J. Public Health 2020; 64:S102-s104Chatterjee PK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496236>
55. **How Indians responded to the Arogya Setu app?** Indian J. Public Health 2020; 64:S228-s230Kodali PB, Hense S, Kopparty S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496261>
56. **Significance of super spreader events in COVID-19.** Indian J. Public Health 2020; 64:S139-s141Kumar S, Jha S, Rai SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496245>
57. **Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.** Indian J. Public Health 2020; 64:S156-s167Lahiri A, Jha SS, Bhattacharya S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496248>
58. **Insights from COVID-19 cluster containment in Bhilwara District, Rajasthan.** Indian J. Public Health 2020; 64:S177-s182Meghwal B, Behera S, Dhariwal AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496251>
59. **A science-based response to COVID-19.** Indian J. Public Health 2020; 64:S90Muliylil JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496231>
60. **Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.** Indian J. Public Health 2020; 64:S142-s146Patel P, Athotra A, Vaisakh TP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496246>
61. **Kerala's response to COVID-19.** Indian J. Public Health 2020; 64:S99-s101Sadanandan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496235>
62. **Containing the first outbreak of COVID-19 in a healthcare setting in India: The sree chitra experience.** Indian J. Public Health 2020; 64:S240-s242Singh G, Srinivas G, Jyothi EK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496265>
63. **Health systems preparedness for COVID-19 pandemic.** Indian J. Public Health 2020; 64:S91-s93Sundararaman T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496232>
64. **An epidemiological study of laboratory confirmed COVID-19 cases admitted in a tertiary care hospital of Pune, Maharashtra.** Indian J. Public Health 2020; 64:S183-s187Tambe MP, Parande MA, Tapare VS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496252>
65. **Lack of transparency during the COVID-19: nurturing a future and more devastating crisis.** Infect Control Hosp Epidemiol 2020;1-3Brailion A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489164>
66. **SARS-CoV-2: The viral shedding vs infectivity dilemma.** Infect Dis Health 2020; Widders A, Broom A, Broom J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473952>
67. **The Greek Response to COVID-19: A True Success Story from an IBD Perspective.** Inflamm. Bowel Dis. 2020; Bamias G, Lagou S, Gizis M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476001>
68. **COVID-19 Outbreak in North Italy: An Overview on Dentistry. A Questionnaire Survey.** Int J Environ Res Public Health 2020; 17Cagetti MG, Cairolì JL, Senna A, Campus G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32481672>
69. **Sociodemographic Predictors of Health Risk Perception, Attitude and Behavior Practices Associated with Health-Emergency Disaster Risk Management for Biological Hazards: The Case of COVID-19 Pandemic in Hong Kong, SAR China.** Int J Environ Res Public Health 2020; 17Chan EYY, Huang Z, Lo ESK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485979>
70. **Forecast Possible Risk for COVID-19 Epidemic Dissemination Under Current Control Strategies in Japan.** Int J Environ Res Public Health 2020; 17Chen Z, Yang J, Dai B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486011>
71. **Spatial Statistics and Influencing Factors of the COVID-19 Epidemic at Both Prefecture and County Levels in Hubei Province, China.** Int J Environ Res Public Health 2020; 17Xiong Y, Wang Y, Chen F, Zhu M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486403>
72. **A Comparison of Infection Venues of COVID-19 Case Clusters in Northeast China.** Int J Environ Res Public Health 2020; 17Zhao P, Zhang N, Li Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503192>



73. **Inequalities in access to water and soap matter for the COVID-19 response in sub-Saharan Africa.** *Int J Equity Health* 2020; 19:82Jiwani SS, Antiporta DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493409>
74. **Air Pollution and temperature are associated with increased COVID-19 incidence: a time series study.** *Int J Infect Dis* 2020; Li H, Xu XL, Dai DW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502664>
75. **COVID-19 Outbreak in Malaysia: Actions Taken by the Malaysian Government.** *Int J Infect Dis* 2020; Shah AUM, Safri SNA, Thevadas R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497808>
76. **Early characteristics of the COVID-19 outbreak predict the subsequent epidemic size.** *Int J Infect Dis* 2020; Zhang L, Tao Y, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502662>
77. **Coronavirus disease 2019 (COVID-19): strengthening our resolve to achieve universal palliative care.** *Int Nurs Rev* 2020; Rosa WE, Davidson PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495339>
78. **Risk of a second wave of Covid-19 infections: using artificial intelligence to investigate stringency of physical distancing policies in North America.** *Int. Orthop.* 2020; Vaid S, McAdie A, Kremer R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504213>
79. **Local Government Efforts to Mitigate the Novel Coronavirus Pandemic among Older Adults.** *J Aging Soc Policy* 2020:1-11Angel JL, Mudrazija S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501753>
80. **COVID-19 Pandemic: Exacerbating Racial/Ethnic Disparities in Long-Term Services and Supports.** *J Aging Soc Policy* 2020:1-11Shippee TP, Akosionu O, Ng W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476614>
81. **Characteristics of U.S. Nursing Homes with COVID-19 Cases.** *J Am Geriatr Soc* 2020; Abrams HR, Loomer L, Gandhi A, Grabowski DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484912>
82. **The role of asymptomatic class, quarantine and isolation in the transmission of COVID-19.** *J. Biol. Dyn.* 2020; 14:389-408Ali M, Shah STH, Imran M, Khan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498655>
83. **Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: A descriptive study.** *J Clin Virol* 2020; 129:104475Yang L, Liu J, Zhang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485619>
84. **Epidemiology of the 2020 Pandemic of COVID-19 in the State of Texas: The First Month of Community Spread.** *J. Community Health* 2020; Khose S, Moore JX, Wang HE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500438>
85. **COVID-19 Pandemic Triggers Telemedicine Regulation and Intensifies Diabetes Management Technology Adoption in Brazil.** *J. Diabetes Sci. Technol.* 2020:1932296820930033Teles M, Sacchetta T, Matsumoto Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482098>
86. **Early SNS-based monitoring system for the COVID-19 outbreak in Japan: a population-level observational study.** *J. Epidemiol.* 2020; Yoneoka D, Kawashima T, Tanoue Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475884>
87. **Practical Implications of Physical Distancing, Social Isolation, and Reduced Physicality for Older Adults in Response to COVID-19.** *J Gerontol Soc Work* 2020:1-3Campbell AD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501151>
88. **Clinical assessment of COVID-19 outbreak among migrant workers residing in a large dormitory in Singapore.** *J Hosp Infect* 2020; Chew MH, Koh FH, Wu JT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492454>
89. **High SARS-CoV-2 Antibody Prevalence among Healthcare Workers Exposed to COVID-19 Patients.** *J Infect* 2020; Chen Y, Tong X, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504745>
90. **Dynamic variations of the COVID-19 disease at different quarantine strategies in Wuhan and mainland China.** *J Infect Public Health* 2020; Cui Q, Hu Z, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493669>
91. **Supporting individuals with intellectual and developmental disability during the first 100 days of the COVID-19 outbreak in the USA.** *J. Intellect. Disabil. Res.* 2020; Mills WR, Sender S, Lichtefeld J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490559>
92. **Letter to the Editor: Assessing the Long-Term Potential of Relaxing Regulations: Should We Go Back to Business as Usual?** *J. Laparoendosc. Adv. Surg. Tech. A* 2020; Jabbour N, Carlis A, Orthopoulos G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498653>
93. **Quantifying the role of social distancing, personal protection and case detection in mitigating COVID-19 outbreak in Ontario, Canada.** *J Math Ind* 2020; 10:15Wu J, Tang B, Bragazzi NL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501416>
94. **Considerations for an Individual-Level Population Notification System for Pandemic Response: A Review and Prototype.** *J Med Internet Res* 2020; 22:e19930Sakib MN, Butt ZA, Morita PP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484443>
95. **SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences.** *J Med Virol* 2020; Lotfi M, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492197>
96. **OVERCOMING THE COVID-19 CRISIS AND PLANING FOR THE FUTURE.** *J Nucl Med* 2020; LoGiudice SH, Liebhauer A, Schoder H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482789>
97. **Estimate of the Basic Reproduction Number for COVID-19: A Systematic Review and Meta-analysis.** *J Prev Med Public Health* 2020; 53:151-157Alimohamadi Y, Taghdir M, Sepandi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498136>
98. **Characteristics of the COVID-19 Outbreak in Korea From the Mass Infection Perspective.** *J Prev Med Public Health* 2020; 53:168-170Kang YJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498139>
99. **Forecasting COVID-19 Transmission and Healthcare Capacity in Bali, Indonesia.** *J Prev Med Public Health* 2020; 53:158-163Wirawan IMA, Januraga PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498137>
100. **Racial disparities in knowledge, attitudes and practices related to COVID-19 in the USA.** *J Public Health (Oxf)* 2020; Alobuia WM, Dalva-Baird NP, Forrester JD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490519>
101. **The Faith Community and the SARS-CoV-2 Outbreak: Part of the Problem or Part of the Solution?** *J Relig Health* 2020; Levin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488827>
102. **Exposure to SARS-CoV-2 in a high transmission setting increases the risk of severe COVID-19 compared to exposure to a low transmission setting?** *J Travel Med* 2020; Chen D, Hu C, Su F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502262>



103. **The potential transmission of SARS-CoV-2 from patients with negative RT-PCR swab tests to others: two related clusters of COVID-19 outbreak.** *Jpn. J. Infect. Dis.* 2020; Cao G, Tang S, Yang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475877>
104. **Epidemic characteristics of COVID-19 in four Chinese cities.** *Jpn. J. Infect. Dis.* 2020; Hu J, Rao S, Hu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475873>
105. **A Case of COVID-19 Patient with False-negative for SARS-CoV-2 of Pharyngeal Swab, from a Chinese traveller Returning from Wuhan, Hubei Province, China, January 2020.** *Jpn. J. Infect. Dis.* 2020; Ishikane M, Miyazato Y, Kustuna S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475881>
106. **A Survey of County Health Departments of Kansas Regarding COVID-19.** *Kans J Med* 2020; 13:112-126Raghuveer TS, Zackula RE, Wittler RR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499864>
107. **A data-driven network model for the emerging COVID-19 epidemics in Wuhan, Toronto and Italy.** *Math. Biosci.* 2020:108391Xue L, Jing S, Miller JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497623>
108. **From SARS to COVID-19: the Singapore journey.** *Med. J. Aust.* 2020; Lin RJ, Lee TH, Lye DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474940>
109. **A survey on the impact of the COVID-19 pandemic on motility and functional investigations in Europe and considerations for recommencing activities in the early recovery phase.** *Neurogastroenterol. Motil.* 2020:e13926Tack J, Schol J, Geeraerts A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478910>
110. **Epidemiologic character of COVID-19 in Kazakhstan: A preliminary report.** *North Clin Istanb* 2020; 7:210-213Maukayeva S, Karimova S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478290>
111. **The Impact of Social Distancing on the Transmission of Influenza Virus, South Korea, 2020.** *Osong Public Health Res Perspect* 2020; 11:91-92Choe YJ, Lee JK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494566>
112. **COVID-19 Outbreak in Malaysia.** *Osong Public Health Res Perspect* 2020; 11:93-100Elengoe A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494567>
113. **Forecasting the prevalence of COVID-19 outbreak in Egypt using nonlinear autoregressive artificial neural networks.** *Process Saf Environ Prot* 2020; 141:1-8Saba AI, Elsheikh AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501368>
114. **Modeling compliance with COVID-19 prevention guidelines: the critical role of trust in science.** *Psychol Health Med* 2020:1-12Plohl N, Musil B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479113>
115. **COVID-19 spread: The Italian case.** *Respir Med Res* 2020; 78:100771Harari S, Vitacca M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502937>
116. **Factors determining the diffusion of COVID-19 and suggested strategy to prevent future accelerated viral infectivity similar to COVID.** *Sci Total Environ* 2020; 729:138474Coccia M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498152>
117. **Wastewater surveillance for population-wide Covid-19: The present and future.** *Sci Total Environ* 2020; 736:139631Daughton CG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474280>
118. **COVID-19's impact on the atmospheric environment in the Southeast Asia region.** *Sci Total Environ* 2020; 736:139658Kanniah KD, Kamarul Zaman NAF, Kaskaoutis DG, Latif MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492613>
119. **Temperature and precipitation associate with Covid-19 new daily cases: A correlation study between weather and Covid-19 pandemic in Oslo, Norway.** *Sci Total Environ* 2020; 737:139659Menebo MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492607>
120. **Statistical Explorations and Univariate Timeseries Analysis on COVID-19 Datasets to Understand the Trend of Disease Spreading and Death.** *Sensors (Basel)* 2020; 20Chatterjee A, Gerdes MW, Martinez SG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486055>
121. **Risk estimation of the SARS-CoV-2 acute respiratory disease outbreak outside China.** *Theor. Biol. Med. Model.* 2020; 17:9Kim S, Choi S, Ko Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498721>
122. **Exploring the roles of high-speed train, air and coach services in the spread of COVID-19 in China.** *Transp Policy (Oxf)* 2020; 94:34-42Zhang Y, Zhang A, Wang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501380>
123. **Contact tracing: a lesson from the Nipah virus in the time of COVID-19.** *Trop. Doct.* 2020:49475520928217Wilson A, Warriar A, Rathish B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476600>
124. **[Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.].** *Vopr. Virusol.* 2020; 65:6-15Lvov DK, Alkhovsky SV, Kolobukhina LV, Burtseva EI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496715>
125. **Evidence of initial success for China exiting COVID-19 social distancing policy after achieving containment.** *Wellcome Open Res* 2020; 5:81Ainslie KEC, Walters CE, Fu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500100>
126. **Disability-inclusive COVID-19 response: What it is, why it is important and what we can learn from the United Kingdom's response.** *Wellcome Open Res* 2020; 5:79Kuper H, Banks LM, Bright T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500099>

## Gastro-enterology-hepatology (20 articles)

1. **Coronavirus disease 2019 (COVID-19) and ischemic colitis: An under-recognized complication.** *Am J Emerg Med* 2020; Chan KH, Lim SL, Damati A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499176>
2. **Gastrointestinal endoscopy operation--A potential transmission risk for SARS-CoV-2.** *Am. J. Infect. Control* 2020; Tan C, Xiao Y, Wu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485277>
3. **Improved safety of endoscopic vessel harvesting during the COVID-19 pandemic.** *Ann Thorac Surg* 2020; Ali Hassan SM, Palacios CM, Ethier T, Bisleri G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504604>
4. **[Increased risk of deep vein thrombosis in intensive care unit patients with CoViD-19 infections?-Preliminary data].** *Chirurg* 2020; Zerwes S, Hernandez Cancino F, Liebetrau D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504106>

5. **ENDOSCOPIC FINDINGS IN PATIENTS INFECTED WITH 2019 NOVEL CORONAVIRUS IN LOMBARDY, ITALY.** *Clin Gastroenterol Hepatol* 2020; Massironi S, Viganò C, Dioscoridi L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480008>
6. **Rates of symptomatic SARS-CoV-2 infection in patients with autoimmune liver diseases in Northern Italy: a telemedicine study.** *Clin Gastroenterol Hepatol* 2020; Rigamonti C, Cittone MG, De Benedittis C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480009>
7. **Atypical presentations of coronavirus disease 2019 in a patient with acute obstructive suppurative cholangitis.** *Clin Res Hepatol Gastroenterol* 2020; Zhai LL, Xiang F, Wang W *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482542>
8. **The influence of the SARS-CoV-2 pandemic on esophagogastric cancer services: an international survey of esophagogastric surgeons.** *Dis. Esophagus* 2020; Kamarajah SK, Markar SR, Singh P, Griffiths EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500134>
9. **Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease.** *Gastroenterology* 2020; Lukin DJ, Kumar A, Hajifathalian K *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479824>
10. **Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey.** *Inflamm. Bowel Dis.* 2020; Martin Arranz E, Suarez Ferrer C, Garcia Ramirez L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495826>
11. **COVID 19 and laparoscopic surgeons, the Indian scenario - Perspective.** *Int J Surg* 2020; Gupta N, Agrawal H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479915>
12. **Patterns of endoscopic during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice.** *Intest Res* 2020; Chen Y, Yu Q, Farraye FA *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475088>
13. **Development and Validation of a Clinical Risk Score for Intensive Care Resource Utilization After Colon Cancer Surgery: a Practical Guide to the Selection of Patients During COVID-19.** *J Gastrointest Surg* 2020; Garfinkle R, Abou-Khalil M, Salama E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495141>
14. **SARS-CoV-2: is the liver merely a bystander to severe disease?** *J Hepatol* 2020; Bangash MN, Patel JM, Parekh D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502510>
15. **Indian Association of Gastrointestinal Endo Surgeons COVID-19 endoscopy recommendations.** *J. Minim. Access Surg.* 2020; 16:201-205 Sundaram E, Manickavasagam K, Goel R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503959>
16. **SARS-CoV-2 Infection and the Liver.** *Pathogens* 2020; 9Morgan K, Samuel K, Vandeputte M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486188>
17. **Outcome of COVID-19 in Liver Transplant Recipients: a Preliminary Report from Northwestern Italy.** *Transpl Infect Dis* 2020:e13353 Patrono D, Lupo F, Canta F *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500942>
18. **[Surgery during the SARS-CoV-2 pandemic : Recommendations on operative procedures].** *Unfallchirurg* 2020; Mahlke L, Flohe S, Matthes G *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488319>
19. **Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review.** *World J. Gastroenterol.* 2020; 26:2323-2332 Cha MH, Regueiro M, Sandhu DS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476796>
20. **Liver diseases in COVID-19: Etiology, treatment and prognosis.** *World J. Gastroenterol.* 2020; 26:2286-2293 Wu J, Song S, Cao HC, Li LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476793>

## Guidelines -Consensus (18 articles)

1. **Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report.** *Chest* 2020; Moores LK, Tritschler T, Brosnahan S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502594>
2. **Practical Guidelines for Collection, Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens.** *Curr Protoc Cytom* 2020; 93:e77 Bain W, Lee JS, Watson AM, Stitt-Fischer MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502333>
3. **Proposed guidelines for screening of hyperglycemia in patients hospitalized with COVID-19 in low resource settings.** *Diabetes Metab Syndr* 2020; 14:753-756 Goyal A, Gupta S, Gupta Y, Tandon N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502958>
4. **Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Herman P, Vincent C, Parietti Winkler C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482571>
5. **Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).** *Eur Heart J* 2020; Anker SD, Butler J, Khan MS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498081>
6. **Exercise in the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) era: A Question and Answer session with the experts Endorsed by the section of Sports Cardiology & Exercise of the European Association of Preventive Cardiology (EAPC).** *Eur J Prev Cardiol* 2020:2047487320930596 Bhatia RT, Marwaha S, Malhotra A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475157>
7. **Rural and Remote Cardiology During the COVID-19 Pandemic: Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement.** *Heart Lung Circ.* 2020; Arnold RH, Tideman PA, Devlin GP *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487432>
8. **Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement from the Cardiac Society of Australia and New Zealand (CSANZ).** *Heart Lung Circ.* 2020; Nicholls SJ, Nelson M, Astley C *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473781>
9. **ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak: Endorsed by the American College of Cardiology.** *J. Am. Soc.*

- [Echocardiogr. 2020; 33:648-653](http://www.ncbi.nlm.nih.gov/pubmed/?term=32503700)Kirkpatrick JN, Mitchell C, Taub C *et al.*
10. **Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic.** *J Eur Acad Dermatol Venereol* 2020; Chernyshov PV, Tomas-Aragones L, Augustin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498128>
  11. **Development and Validation of a Clinical Risk Score for Intensive Care Resource Utilization After Colon Cancer Surgery: a Practical Guide to the Selection of Patients During COVID-19.** *J Gastrointest Surg* 2020; Garfinkle R, Abou-Khalil M, Salama E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495141>
  12. **ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.** *J. Med. Toxicol.* 2020; Stolbach AI, Mazer-Amirshahi M, Marino R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500283>
  13. **Indian Association of Gastrointestinal Endo Surgeons COVID-19 endoscopy recommendations.** *J. Minim. Access Surg.* 2020; 16:201-205 Sundaram E, Manickavasagam K, Goel R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503959>
  14. **COVID-19: Preliminary Clinical Guidelines for Ophthalmology Practices.** *Med Hypothesis Discov Innov Ophthalmol* 2020; 9:149-158 Gharebaghi R, Desuatels J, Moshirfar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490022>
  15. **A Guiding Principles Checklist for Otolaryngologic Surgery in the COVID-19 Era.** *Otolaryngol Head Neck Surg* 2020:194599820933253 Valika TS, Maurrasse SE, Thompson DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482124>
  16. **Chinese Society of Interventional Radiology Expert Consensus on the prevention and control of COVID-19 in interventional radiology procedures (first edition).** *Quant Imaging Med Surg* 2020; 10:1045-1057 Zhu Y, He Y, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489928>
  17. **Recommendations of the Thoracic Imaging Section of the German Radiological Society for clinical application of chest imaging and structured CT reporting in the COVID-19 pandemic.** *RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin* 2020; Vogel-Claussen J, Ley-Zaporozhan J, Agarwal P *et al.*
  18. **Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).** *Vasa* 2020:1-5 Linnemann B, Bauersachs R, Grebe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501145>

## Imaging (21 articles)

1. **Systematic Review and Meta-Analysis on the Value of Chest CT in the Diagnosis of Coronavirus Disease (COVID-19): Sol Scientiae, Illustra Nos.** *AJR Am J Roentgenol* 2020:1-9 Adams HJA, Kwee TC, Yakar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478562>
2. **Lung ultrasound monitoring in patients with COVID-19 on home isolation.** *Am J Emerg Med* 2020; Shokoohi H, Duggan NM, Garcia-de-Casasola Sanchez G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482483>
3. **The role of pulmonary CT scans for children during the COVID-19 pandemic.** *BMC Med* 2020; 18:171 Sinha IP, Kaleem M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498685>
4. **Incidental CT findings in the lungs in COVID-19 patients presenting with abdominal pain.** *Clin Imaging* 2020; 67:1-4 Voutsinas N, Toussie D, Jacobi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492557>
5. **Weakly Labeled Data Augmentation for Deep Learning: A Study on COVID-19 Detection in Chest X-Rays.** *Diagnostics (Basel)* 2020; 10 Rajaraman S, Antani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486140>
6. **Point-of-care lung ultrasound in three neonates with COVID-19.** *Eur. J. Pediatr.* 2020; Gregorio-Hernandez R, Escobar-Izquierdo AB, Cobas-Pazos J, Martinez-Gimeno A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504135>
7. **CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients.** *Eur Radiol* 2020; Ojha V, Mani A, Pandey NN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474632>
8. **Radiographic findings in 240 patients with COVID-19 pneumonia: time-dependence after the onset of symptoms.** *Eur Radiol* 2020; Vancheri SG, Saviotto G, Ballati F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474630>
9. **COVID-19 Incidentally Detected on PET/CT During Work-up for Locally Advanced Head and Neck Cancer.** *In Vivo* 2020; 34:1681-1684 Mo A, Brodin NP, Tome WA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503829>
10. **A modified deep convolutional neural network for detecting COVID-19 and pneumonia from chest X-ray images based on the concatenation of Xception and ResNet50V2.** *Inform Med Unlocked* 2020; 19:100360 Rahimzadeh M, Attar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501424>
11. **ASE Statement on Point-of-Care Ultrasound during the 2019 Novel Coronavirus Pandemic.** *J. Am. Soc. Echocardiogr.* 2020; 33:670-673 Johri AM, Galen B, Kirkpatrick JN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503704>
12. **Bedside Focused Cardiac Ultrasound in COVID-19 from the Wuhan Epicenter: The Role of Cardiac Point-of-Care Ultrasound, Limited Transthoracic Echocardiography, and Critical Care Echocardiography.** *J. Am. Soc. Echocardiogr.* 2020; 33:676-682 Zhang L, Wang B, Zhou J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503706>
13. **Clinical Potential of UTE-MRI for Assessing COVID-19: Patient- and Lesion-Based Comparative Analysis.** *J. Magn. Reson. Imaging* 2020; Yang S, Zhang Y, Shen J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491257>
14. **Lung Ultrasound Can Influence the Clinical Treatment of Pregnant Women With COVID-19.** *J Ultrasound Med* 2020; Yassa M, Birol P, Mutlu AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478445>
15. **Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge.** *J Xray Sci Technol* 2020; Wei J, Lei P, Yang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474479>



16. **Coronavirus disease 2019: initial high resolution computed tomography imaging feature analysis: report of seven cases.** *Jpn. J. Infect. Dis.* 2020; Huang J, Ding J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475876>
17. **A systematic review of chest imaging findings in COVID-19.** *Quant Imaging Med Surg* 2020; 10:1058-1079 Sun Z, Zhang N, Li Y, Xu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489929>
18. **Radiology of COVID-19 Pneumonia - Pictorial Essay and Structured Reporting.** *RoFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin* 2020; 192:513-517 Schaible J, Meiler S, Poschenrieder F *et al.*
19. **Recommendations of the Thoracic Imaging Section of the German Radiological Society for clinical application of chest imaging and structured CT reporting in the COVID-19 pandemic.** *RoFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin* 2020; Vogel-Claussen J, Ley-Zaporozhan J, Agarwal P *et al.*
20. **Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan, China.** *Theranostics* 2020; 10:6113-6121 Li L, Yang L, Gui S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483442>
21. **Role of point-of-care ultrasound during the COVID-19 pandemic: our recommendations in the management of dialytic patients.** *Ultrasound J* 2020; 12:30 Vieira ALS, Pazeli Junior JM, Bastos MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488686>

## Immune response (16 articles)

1. **Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19).** *Aging Dis* 2020; 11:642-648 Dong X, Wang M, Liu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489708>
2. **Type 3 hypersensitivity in COVID-19 vasculitis.** *Clin Immunol* 2020:108487 Roncati L, Ligabue G, Fabbiani L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479986>
3. **Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines.** *Cureus* 2020; 12:e8399 Manners C, Larios Bautista E, Sidoti H, Lopez OJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499988>
4. **Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.** *Emerg Microbes Infect* 2020; 9:1096-1101 Shen L, Wang C, Zhao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476607>
5. **Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.** *Int J Infect Dis* 2020; Kang CK, Han GC, Kim M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492530>
6. **Reply to Carvalho.** *J Allergy Clin Immunol Pract* 2020; Nyenhuis SM, Greiwe J, Zeiger JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474131>
7. **SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines.** *J Biol Regul Homeost Agents* 2020; 34 Ronconi G, Tete G, Kritas SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476380>
8. **Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).** *J. Biomed. Sci.* 2020; 27:72 Chang FY, Chen HC, Chen PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498686>
9. **Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of COVID-19 patient with diarrhea.** *J Med Virol* 2020; Carnevale S, Beretta P, Morbini P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492199>
10. **Endothelial cell infection and endotheliitis in COVID-19.** *The Lancet* 2020; 395:1417-1418 Varga Z, Flammer AJ, Steiger P *et al.*
11. **The immune system and COVID-19: Friend or foe?** *Life Sci* 2020:117900 Yazdanpanah F, Hamblin MR, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502542>
12. **COVID-19: Loss of bridging between innate and adaptive immunity?** *Med. Hypotheses* 2020; 144:109861 Rao VUS, Arakeri G, Subash A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32505066>
13. **Thromboinflammatory response in SARS-CoV-2 sepsis.** *Med. Leg. J.* 2020:25817220926915 Maiese A, Passaro G, Matteis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490726>
14. **Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.** *N Engl J Med* 2020; Ackermann M, Verleden SE, Kuehnel M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32437596>
15. **COVID-19: the vasculature unleashed.** *Nat. Rev. Immunol.* 2020; Teuwen LA, Geldhof V, Pasut A, Carmeliet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32439870>
16. **An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies.** *Travel Med Infect Dis* 2020:101755 Dhama K, Patel SK, Pathak M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479816>

## Management – misc. diseases (110 articles)

1. **COVID 19: Surgery & the question of race.** *Am. J. Surg.* 2020; Collier KT, Rothstein DH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498946>
2. **Expedited SARS-CoV-2 Screening of Donors and Recipients Supports Continued Solid Organ Transplant.** *Am J Transplant* 2020; Lieberman JA, Mays JA, Wells C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476285>
3. **Orthopedic healthcare in the time of COVID-19: Experience of the orthopedic surgery department at Mustapha Bacha Hospital, Algeria.** *Ann Med Surg (Lond)* 2020; 55:164-166 Meraghni N, Benkaidali R, Derradji M, Kara Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483487>
4. **Improved safety of endoscopic vessel harvesting during the COVID-19 pandemic.** *Ann Thorac Surg* 2020; Ali Hassan SM, Palacios CM, Ethier T, Bisleri G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504604>
5. **Principles for Managing Patients with Spinal Ailments in the Coronavirus Disease 2019 Era: What Do We Know So Far? An Evidence-Based, Narrative Review.** *Asian Spine J* 2020; Viswanathan VK, Subramanian S, Rao AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493004>



6. **A brave new world: the new normal for general practice after the COVID-19 pandemic.** *BJGP Open* 2020; Khan N, Jones D, Grice A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487520>
7. **Provision of Emergency Maxillofacial Service During the COVID-19 Pandemic : A Collaborative Five Centre UK Study.** *Br. J. Oral Maxillofac. Surg.* 2020; Blackhall KK, Downie IP, Ramchandani P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482348>
8. **Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST).** *Breast* 2020; 52:110-115 Gasparri ML, Gentilini OD, Lueftner D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502796>
9. **Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.** *Cancer* 2020; Baumann BC, MacArthur KM, Brewer JD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478867>
10. **Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.** *Cancer* 2020; Huang SH, O'Sullivan B, Su J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478895>
11. **COVID-19 and heme oxygenase: novel insight into the disease and potential therapies.** *Cell Stress Chaperones* 2020; Hooper PL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500379>
12. **Oncology Treatment in the Era of COVID-19: We Cannot Afford to Hit the Pause Button.** *Clin Pharmacol Ther* 2020; Holstein SA, Vose JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484908>
13. **Impact of COVID-19 on Canadian medical oncologists and cancer care: Canadian Association of Medical Oncologists survey report.** *Curr. Oncol.* 2020; 27:71-74 Gill S, Hao D, Hirte H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489248>
14. **Influence of COVID-19 pandemic on hospitalizations at the tertiary dermatology department in south-west Poland.** *Dermatol Ther* 2020; Bialynicki-Birula R, Siemasz I, Otłowska A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478949>
15. **Laser Safety Measures for The Treatment of Genital Warts in Hiv+ Patients During The Covid-19 Pandemic.** *Dermatol Ther* 2020:e13750 Cameli N, Mariano M, Latini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495468>
16. **Recommendations for Diagnosis and Treatment of Onychomycosis During the COVID-19 Pandemic.** *Dermatol Ther* 2020:e13709 Lipner SR, Ricardo JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474984>
17. **Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment.** *Dermatol Ther* 2020; Magnano M, Balestri R, Bardazzi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475056>
18. **Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.** *Dermatol Ther* 2020:e13722 Melis D, Mugheddu C, Sanna S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475036>
19. **How Can I Take Care Of You? The Dermatologist Meets Patients' Needs During The Covid19 Pandemic.** *Dermatol Ther* 2020; Radi G, Simonetti O, Diotallevi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478970>
20. **Recommendations for Treatment of Nail Psoriasis During the COVID-19 Pandemic.** *Dermatol Ther* 2020:e13757 Ricardo JW, Lipner SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495952>
21. **Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience.** *Dermatol Ther* 2020:e13765 Rossi M, Rovati C, Arisi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500660>
22. **Global Coronavirus Pandemic (SARS CoV-2): Past, Present, And Future Of Pediatric Dermatology.** *Dermatol Ther* 2020:e13767 Simonetti O, Diotallevi F, Campanati A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500648>
23. **Psoriatic Arthritis and COVID-19 Pandemic: Consequences in Medical Treatment?** *Dermatol Ther* 2020:e13743 Wollina U, Fioranelli M, Goldust M, Lotti T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478971>
24. **Management of diabetic persons with foot ulceration during COVID-19 health care emergency: effectiveness of a new triage pathway.** *Diabetes Res Clin Pract* 2020:108245 Marco M, Valentina I, Laura G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497745>
25. **The influence of the SARS-CoV-2 pandemic on esophagogastric cancer services: an international survey of esophagogastric surgeons.** *Dis. Esophagus* 2020; Kamarajah SK, Markar SR, Singh P, Griffiths EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500134>
26. **The public health response to the COVID-19 pandemic for people with disabilities.** *Disabil Health J* 2020:100943 Boyle CA, Fox MH, Haverkamp SM, Zubler J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499132>
27. **Role of pharmacists in COVID-19 disease: a Jordanian perspective.** *Disaster Med Public Health Prep* 2020:1-17 Abdel Jalil MH, Alsous MM, Abu Hammour K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498749>
28. **Psoriasis, biologic therapy, and the pandemic of the 21st century.** *Drugs Context* 2020; 9 Nogueira M, Vender R, Torres T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32477419>
29. **Effect of shelter-in-place on emergency department radiology volumes during the COVID-19 pandemic.** *Emerg Radiol* 2020; Houshyar R, Tran-Harding K, Glavis-Bloom J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504280>
30. **[The effects of quarantine for SARS-CoV-2 on sleep: An online survey].** *Encephale* 2020; Hartley S, Colas des Francs C, Aussert F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475692>
31. **Endocrine surgery during COVID-19 pandemic: do we need an update of indications in Italy?** *Endocrine* 2020; Lombardi CP, D'Amore A, Grani G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500518>
32. **Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Herman P, Vincent C, Parietti Winkler C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482571>
33. **Thoracic surgeons' insights: Improving thoracic surgery outcomes during the Coronavirus Disease 2019 pandemic.** *Eur J Cardiothorac Surg* 2020; Chen KN, Gao S, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496537>
34. **2020PMD, 30-years of Translational Mobility Medicine at the time of COVID-19 outbreak: Last-minute forewords from the editor.** *Eur. J. Transl. Myol.* 2020; 30:8966 Carraro U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499903>

35. **Is it Possible to Safely Maintain a Regular Vascular Practice During the COVID-19 Pandemic?** *Eur. J. Vasc. Endovasc. Surg.* 2020; Pini R, Faggioli G, Vacirca A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499169>
36. **Learning from the past: did experience with previous epidemics help mitigate the impact of COVID-19 among spine surgeons worldwide?** *Eur. Spine J.* 2020; Weiner JA, Swiatek PR, Johnson DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500177>
37. **Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.** *Front. Immunol.* 2020; 11:1059Mohn N, Pul R, Kleinschnitz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32477373>
38. **Emergency ophthalmic surgeries during COVID-19-a Hong Kong perspective.** *Graefes Arch Clin Exp Ophthalmol* 2020; Tang EWH, Wong DHT, Chan YYY, Li KKW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494874>
39. **COVID-19 and hand surgery.** *Hand Surg Rehabil* 2020; Yasri S, Wiwanitkit V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474123>
40. **Clinical and surgical management of patients with head and neck cancer in a COVID-19 dedicated center in Italy.** *Head Neck* 2020; Galli J, Settimi S, Tricarico L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476204>
41. **Telemedicine for head and neck ambulatory visits during COVID-19: Evaluating usability and patient satisfaction.** *Head Neck* 2020; Layfield E, Triantafyllou V, Prasad A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476228>
42. **Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors.** *Immunotherapy* 2020; Vici P, Pizzuti L, Krasniqi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489118>
43. **Tor Vergata University-Hospital in the Beginning of COVID-19-Era: Experience and Recommendation for Breast Cancer Patients.** *In Vivo* 2020; 34:1661-1665Buonomo OC, Materazzo M, Pellicciaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503826>
44. **Breast Cancer Surgery During the COVID-19 Pandemic: An Observational Clinical Study of the Breast Surgery Clinic at Ospedale Policlinico San Martino - Genoa, Italy.** *In Vivo* 2020; 34:1667-1673Fregatti P, Gipponi M, Giacchino M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503827>
45. **Breast Cancer and COVID-19: The Effect of Fear on Patients' Decision-making Process.** *In Vivo* 2020; 34:1651-1659Vanni G, Materazzo M, Pellicciaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503825>
46. **The Effect of Coronavirus (COVID-19) on Breast Cancer Teamwork: A Multicentric Survey.** *In Vivo* 2020; 34:1685-1694Vanni G, Materazzo M, Santori F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503830>
47. **Radiation Therapy During the COVID-19 Pandemic: Experience from Beijing, China.** *In Vivo* 2020; 34:1675-1680Wang W, Liu X, Zhang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503828>
48. **Severe Complicated Influenza Declined During the Prevention of COVID-19 in Taiwan.** *Infect Control Hosp Epidemiol* 2020;1-8Yang CJ, Chen TC, Kuo SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489160>
49. **The impact of COVID-19 pandemic in the colorectal cancer prevention.** *Int. J. Colorectal Dis.* 2020; Del Vecchio Blanco G, Calabrese E, Biancone L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500432>
50. **Eating and exercise behaviors in eating disorders and the general population during the COVID-19 pandemic in Australia: Initial results from the COLLATE project.** *Int. J. Eat. Disord.* 2020; Phillipou A, Meyer D, Neill E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476163>
51. **The impact of the COVID-19 pandemic on eating disorder risk and symptoms.** *Int. J. Eat. Disord.* 2020; Rodgers RF, Lombardo C, Cerolini S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476175>
52. **COVID-19 Outbreak Perception in Italian Dentists.** *Int J Environ Res Public Health* 2020; 17De Stefani A, Bruno G, Mutinelli S, Gracco A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485959>
53. **Does COVID-19 infection impact on the trend of seasonal influenza infection? 11 countries and regions, from 2014 to 2020.** *Int J Infect Dis* 2020; Itaya T, Furuse Y, Jindai K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492532>
54. **Perspectives on how to navigate cancer surgery in the breast, head and neck, skin, and soft tissue tumor in limited-resource countries during COVID-19 pandemic.** *Int J Surg* 2020; Anwar SL, Harahap WA, Aryandono T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497751>
55. **Critical adjustments in a department of orthopaedics through the COVID-19 pandemic.** *Int. Orthop.* 2020; Luengo-Alonso G, Perez-Tabernero FG, Tovar-Bazaga M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474718>
56. **Impact of the COroNaVirus Disease 2019 lockdown on hand and upper limb emergencies: experience of a referred university trauma hand centre in Paris, France centre in Paris, France.** *Int. Orthop.* 2020; Pichard R, Kopel L, Lejeune Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488564>
57. **Challenges and countermeasures in the prevention of nosocomial infections of SARS-CoV-2 before resumption of work: implications for the dermatology department.** *J Am Acad Dermatol* 2020; Zhang Y, Wen J, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497702>
58. **Appropriate arrangement of cancer treatment after COVID-19 epidemic peaks in China.** *J. Cancer Res. Clin. Oncol.* 2020; Mo H, Liu B, Ma F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474751>
59. **Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease.** *J. Clin. Anesth.* 2020; 66:109926Taboada M, Caruezo V, Naveira A, Atanassoff PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474331>
60. **Impact of COVID-19 on Urology Practice: A Global Perspective and Snapshot Analysis.** *J Clin Med* 2020; 9Gravas S, Bolton D, Gomez R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503305>
61. **The Aftermath of COVID-19 in Dermatology Practice: What's next?** *J Cosmet Dermatol* 2020; Ng JN, Cembrano KAG, Wanitphakdeedecha R, Manuskiatti W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502318>
62. **Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto.** *J. Cutan. Med. Surg.* 2020:1203475420930226Georgakopoulos JR, Yeung J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475151>
63. **Challenges faced by patients with morphea in the era of SARS-CoV-2.** *J Dermatolog Treat* 2020:1-6Shahidi Dadras M, Namazi N, Nikvar M, Abdollahimajd F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475151>

term=32502370

64. **Sexually Transmitted Infections during the COVID-19 outbreak: comparison of patients referring to the service of sexually transmitted diseases during the sanitary emergency with those referring during the common practice.** *J Eur Acad Dermatol Venereol* 2020; Sacchelli L, Viviani F, Orioni G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491214>
65. **Development and Validation of a Clinical Risk Score for Intensive Care Resource Utilization After Colon Cancer Surgery: a Practical Guide to the Selection of Patients During COVID-19.** *J Gastrointest Surg* 2020; Garfinkle R, Abou-Khalil M, Salama E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495141>
66. **Responsible Return to Essential and Non-Essential Surgery During the COVID-19 Pandemic.** *J Gastrointest Surg* 2020; Poulou BK, Phieffer LS, Mayerson J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500416>
67. **Novel corona virus disease (COVID-19) awareness among the dental interns, dental auxiliaries and dental specialists in Saudi Arabia: A nationwide study.** *J Infect Public Health* 2020; Quadri MFA, Jafer MA, Alqahtani AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475807>
68. **The rediscovery of hydroxychloroquine in allergic diseases in the COVID-19 era.** *J. Investig. Allergol. Clin. Immunol.* 2020;0Bonzano L, Cassone G, Tarallo L, Pellacani G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474406>
69. **Letter to the Editor: Robot-Assisted and Minimally Invasive Pediatric Surgery and Urology During the COVID-19 Pandemic: A Short Literature Review.** *J. Laparoendosc. Adv. Surg. Tech. A* 2020; Esposito C, Masieri L, Castagnetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498612>
70. **National outreach of telepalliative medicine volunteers for a New York City safety net system COVID-19 pandemic response.** *J Pain Symptom Manage* 2020; Israilov S, Krouss M, Zourova M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479861>
71. **COVID - A Caring Reflection.** *J Pastoral Care Counsel* 2020; 74:141 Sylvester AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496947>
72. **Breast reconstruction and the COVID-19 pandemic: A viewpoint.** *J. Plast. Reconstr. Aesthet. Surg.* 2020; Pace BD, Benson JR, Malata CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487361>
73. **How the COVID-19 pandemic changed the Plastic Surgery activity in a regional referral center in Northern Italy.** *J. Plast. Reconstr. Aesthet. Surg.* 2020; Pignatti M, Pinto V, Miralles MEL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499187>
74. **Management of patients with ovarian cancer in the COVID-19 era.** *J. Surg. Oncol.* 2020; Bogani G, Casarin J, Pinelli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476155>
75. **Flattening the curve in oncologic surgery: Impact of Covid-19 on surgery at tertiary care cancer center.** *J. Surg. Oncol.* 2020; Chang EI, Liu JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488866>
76. **Strategy for treating vascular emergencies during the COVID-19 pandemic in China.** *J. Vasc. Surg.* 2020; Wang J, Kuang M, Chen L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497746>
77. **Infection control of operating room and anesthesia for cesarean section during pandemic Coronavirus disease-19 (COVID-19) outbreak in Daegu, the republic of Korea - 8 cases report.** *Korean J Anesthesiol* 2020; Oh J, Kim E, Kim H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498490>
78. **COVID-19: Preliminary Clinical Guidelines for Ophthalmology Practices.** *Med Hypothesis Discov Innov Ophthalmol* 2020; 9:149-158 Gharebaghi R, Desuatsels J, Moshirfar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490022>
79. **COVID-19 and Ophthalmology: A New Chapter in an Old Story.** *Med Hypothesis Discov Innov Ophthalmol* 2020; 9:71-73 Reviglio VE, Osaba M, Reviglio V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490013>
80. **Maximizing the academic nursing model in the era of COVID-19 and beyond.** *Nurs. Outlook* 2020; Bettencourt AP, Vance AJ, Jun J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475612>
81. **Management of neovascular age-related macular degeneration during the COVID-19 pandemic.** *Ophthalmol Retina* 2020; Corradetti G, Corvi F, Nguyen TV, Sadda SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480013>
82. **Time for a Paradigm Shift in Head and Neck Cancer Management During the COVID-19 Pandemic.** *Otolaryngol Head Neck Surg* 2020:194599820931789 Han AY, Miller JE, Long JL, St John MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484380>
83. **Rhinologic Practice Special Considerations During COVID-19: Visit Planning, Personal Protective Equipment, Testing, and Environmental Controls.** *Otolaryngol Head Neck Surg* 2020:194599820933169 Howard BE, Lal D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484728>
84. **Otolaryngology in the Time of Corona: Assessing Operative Impact and Risk during the COVID-19 Crisis.** *Otolaryngol Head Neck Surg* 2020:194599820930214 Kuhar HN, Heilingoetter A, Bergman M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482131>
85. **Back to the Future: Principles on Resuming Outpatient Services in the COVID-19 Era.** *Otolaryngol Head Neck Surg* 2020:194599820933597 Valika TS, Billings KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482142>
86. **A Guiding Principles Checklist for Otolaryngologic Surgery in the COVID-19 Era.** *Otolaryngol Head Neck Surg* 2020:194599820933253 Valika TS, Maurrasse SE, Thompson DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482124>
87. **Care of Patients With a Laryngectomy During the COVID-19 Pandemic.** *Otolaryngol Head Neck Surg* 2020:194599820933185 Yeung DCM, Lai R, Wong EWY, Chan JYK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482154>
88. **Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks.** *Pharmacol. Res.* 2020; 158:104917 Boccanegra B, Verhaar IEC, Cappellari O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485610>
89. **Eating disorders in the age of COVID-19.** *Psychiatry Res* 2020; 290:113122 Shah M, Sachdeva M, Johnston H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480115>
90. **Chinese Society of Interventional Radiology Expert Consensus on the prevention and control of COVID-19 in interventional radiology procedures (first edition).** *Quant Imaging Med Surg* 2020; 10:1045-1057 Zhu Y, He Y, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489928>



91. **Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups.** *Radiat Oncol* 2020; 15:140Vordermark D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493443>
92. **Radiological management of COVID-19: structure your diagnostic path to guarantee a safe path.** *Radiol Med* 2020; Stramare R, Carretta G, Capizzi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500510>
93. **Managing a radiotherapy center safely and efficiently using risk-adaptive strategies during coronavirus disease pandemic: Experience from national cancer center of china.** *Radiother Oncol* 2020; Bi N, Yi J, Dai J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479778>
94. **Evolution of clinical radiotherapy physics practice under COVID-19 constraints.** *Radiother Oncol* 2020; Khan R, Darafsheh A, Goharian M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474126>
95. **Should we embrace hypofractionated radiotherapy for cervical cancer? A technical note on management during the COVID-19 pandemic.** *Radiother Oncol* 2020; Mendez LC, Raziee H, Davidson M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474128>
96. **Mitigating the Impact of COVID-19 on Oncology: Clinical and Operational Lessons from a Prospective Radiation Oncology Cohort Tested for COVID-19.** *Radiother Oncol* 2020; Ning MS, Frances McAleer M, Jeter MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474129>
97. **Spanish risk management framework across 17 radiation oncology centers during COVID-19 pandemic.** *Radiother Oncol* 2020; Suarez V, Moreno-Olmedo E, Perez M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479777>
98. **Community pharmacists' exposure to COVID-19.** *Res Social Adm Pharm* 2020; Cabas P, Di Bella S, Giuffre M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499159>
99. **Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies.** *Res Social Adm Pharm* 2020; Romano S, Galante H, Figueira D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482587>
100. **Impact of the Covid-19 pandemic and lung transplantation program in France.** *Respir Med Res* 2020; 78:100758Picard C, Le Pavec J, Tissot A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474398>
101. **Implications of COVID-19 in pediatric rheumatology.** *Rheumatol. Int.* 2020; Batu ED, Ozen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500409>
102. **Ancillary considerations for endodontic emergency treatment of Covid-19 positive patients.** *Spec. Care Dentist.* 2020; Umer F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501576>
103. **Providing nutritional care to cancer patients during the COVID-19 pandemic: an Italian perspective.** *Support. Care Cancer* 2020; Lobascio F, Caccialanza R, Monaco T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495030>
104. **[Surgery during the SARS-CoV-2 pandemic : Recommendations on operative procedures].** *Unfallchirurg* 2020; Mahlke L, Flohe S, Matthes G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488319>
105. **Resuming elective surgery in the time of COVID-19: a safe and comprehensive strategy.** *Updates Surg.* 2020; Al-Omar K, Bakkar S, Khasawneh L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495280>
106. **Continuing our work: transplant surgery and surgical oncology in a tertiary referral COVID-19 center.** *Updates Surg.* 2020; Berardi G, Colasanti M, Levi Sandri GB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500431>
107. **Concerns in redirecting uro-oncologic patients during COVID-19 pandemic.** *Urology* 2020; Campodonico F, Ennas M, Domenico AD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504678>
108. **Impact of COVID-19 outbreak on acute low back pain.** *World Neurosurg* 2020; Borsa S, Pluderi M, Carrabba G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479910>
109. **Scoring system to triage patients for spine surgery in the setting of limited resources: Application to the COVID-19 pandemic and beyond.** *World Neurosurg* 2020; Sciubba DM, Ehresman J, Pennington Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479913>
110. **Nasoseptal Flap Necrosis After Endoscopic Skull Base Surgery in the Setting of SARS-CoV-2/COVID-19.** *World Neurosurg* 2020; Talmor G, Grube JG, Eloy JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479908>

## Management (30 articles)

1. **Using the prone position could help to combat the development of fast hypoxia in some patients with COVID-19.** *Acta Paediatr* 2020; Lindahl SGE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484966>
2. **Should We Monitor Pulsus Paradoxus via Pulse Oximetry in COVID-19 Patients with Acute Respiratory Failure?** *Am J Respir Crit Care Med* 2020; Michard F, Shelley K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492351>
3. **Application of the PDCA cycle for standardized nursing management in a COVID-19 intensive care unit.** *Ann Palliat Med* 2020; 9:1198-1205Chen Y, Zheng J, Wu D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498535>
4. **Swapping drills for dressings: redeployment of dentists to community nursing.** *Br. J. Community Nurs.* 2020; 25:266-270Johnston L, Archer N, Martin K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496858>
5. **Prone positioning in conscious patients on medical wards: A review of the evidence and its relevance to patients with COVID-19 infection.** *Clin Med (Lond)* 2020; Chad T, Sampson C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503800>
6. **Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.** *Clin Rheumatol* 2020; Soy M, Keser G, Atagunduz P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474885>
7. **In-hospital airway management of COVID-19 patients.** *Crit Care* 2020; 24:292Sullivan EH, Gibson LE, Berra L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503600>
8. **Towards individualized and optimized positioning of non-ventilated COVID-19 patients: Putting the affected parts of the lung(s) on top?** *Diabetes Metab.* 2020; Froelich S, Mandonnet E, Julla JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473964>

9. **Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease.** *Gastroenterology* 2020; Lukin DJ, Kumar A, Hajifathalian K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479824>
10. **[The Key Role of Taiwanese Nurses in Combating COVID-19 Pandemic].** *Hu Li Za Zhi* 2020; 67:84-89Chen SF, Huang LH, Chen CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495333>
11. **[Nursing Experience of Caring for a Patient With COVID-19 During Isolation].** *Hu Li Za Zhi* 2020; 67:111-119Hsu TC, Wu CC, Lai PY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495337>
12. **Novel Coronavirus disease 2019 (COVID-19): new challenges and new responsibilities in developing countries.** *Hum Vaccin Immunother* 2020:1-3Anjum FR, Anam S, Rahman SU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501130>
13. **The armed forces medical services response to COVID-19.** *Indian J. Public Health* 2020; 64:S94-s95Banerji A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496233>
14. **Health systems preparedness during COVID-19 pandemic: China and India.** *Indian J. Public Health* 2020; 64:S96-s98Baru RV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496234>
15. **COVID-19-Hospitalized Patients in Karnataka: Survival and Stay Characteristics.** *Indian J. Public Health* 2020; 64:S221-s224Mishra V, Burma AD, Das SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496259>
16. **Insouciance and inexperience: A deadly combination when dealing with COVID-19.** *Int. J. Health Plann. Manage.* 2020; Paton C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490556>
17. **NANDA-I, NOC, and NIC Linkages to SARS-Cov-2 (Covid-19): Part 1. Community Response.** *Int J Nurs Knowl* 2020; Moorhead S, Macieira TGR, Lopez KD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497413>
18. **Turning a surgical unit into a COVID-19 facility: governance counts. Correspondence.** *Int J Surg* 2020; Sfez M, Derichard A, Cittanova-Pansard ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502703>
19. **Successful use of methylprednisolone for treating severe COVID-19.** *J Allergy Clin Immunol* 2020; Liu J, Zheng X, Huang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479759>
20. **Perianesthetic concerns for the non-COVID-19 patients requiring surgery during the COVID-19 pandemic outbreak: An observational study.** *J. Clin. Anesth.* 2020; 66:109923Boccaro G, Cassagnol D, Bagues L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480207>
21. **COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no influence on the clinical severity and outcome.** *J Infect* 2020; Hu J, Zhang X, Zhang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474032>
22. **Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?** *J Microbiol Immunol Infect* 2020; Lai CC, Wang CY, Hsueh PR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482366>
23. **A Hidden Key to COVID-19 Management in Korea: Public Health Doctors.** *J Prev Med Public Health* 2020; 53:175-177Choi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498141>
24. **The association between treatment with heparin and survival in patients with Covid-19.** *J. Thromb. Thrombolysis* 2020; Ayerbe L, Risco C, Ayis S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476080>
25. **Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Espanola de Ginecología y Obstetricia and Sociedad Espanola de Trombosis y Hemostasia.** *Maturitas* 2020; 137:57-62Ramirez I, De la Viuda E, Baquedano L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498938>
26. **Barriers to conducting deprescribing in the elderly population amid the COVID-19 pandemic.** *Res Social Adm Pharm* 2020; Elbeddini A, Prabaharan T, Almasakhi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499161>
27. **A 55-year-old COVID-19-positive man managed with self-regulation of high-flow oxygen by high-velocity nasal insufflation therapy.** *Respirol Case Rep* 2020; 8:e00591Ciment AJ, Ciment LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489666>
28. **Proposal for the use of anakinra in acute respiratory distress secondary to COVID-19.** *Reumatol. Clin.* 2020; Munoz-Jimenez A, Rubio-Romero E, Marengo de la Fuente JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482538>
29. **Addressing a National Crisis: The Spine Hospital and Department's Response to the COVID-19 Pandemic in New York City.** *Spine J* 2020; Lombardi JM, Bottiglieri T, Desai N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492529>
30. **Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).** *Vasa* 2020:1-5Linnemann B, Bauersachs R, Grebe M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501145>

## Mental – public health (54 articles)

1. **Private metropolitan telepsychiatry in Australia during Covid-19: current practice and future developments.** *Australas Psychiatry* 2020:1039856220930675Looi JC, Pring W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484737>
2. **Ethnic Disparities in Hospitalisation for COVID-19 in England: The Role of Socioeconomic Factors, Mental Health, and Inflammatory and Pro-inflammatory Factors in a Community-based Cohort Study.** *Brain Behav Immun* 2020; Lassale C, Gaye B, Hamer M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497776>
3. **COVID-19 pandemic and mental health consequences: systematic review of the current evidence.** *Brain Behav Immun* 2020; Vindegaard N, Eriksen Benros M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485289>
4. **Psychological and Behavioral Response to the Coronavirus (COVID-19) Pandemic.** *Cureus* 2020; 12:e7923Balkhi F, Nasir A, Zehra A, Riaz R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499970>
5. **COVID-19 Information Seeking on Digital Media and Preventive Behaviors: The Mediation Role of Worry.** *Cyberpsychol Behav Soc Netw* 2020; Liu PL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498549>
6. **COVID-19 Crisis: Early Observations on a Pandemic's Psychiatric Problems.** *Deutsche Medizinische Wochenschrift* 2020; 145:675-681Fatke B, Hölzle P, Frank A, Förstl H.

7. **The public health response to the COVID-19 pandemic for people with disabilities.** *Disabil Health J* 2020;100943Boyle CA, Fox MH, Havercamp SM, Zubler J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499132>
8. **Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis.** *Disabil Health J* 2020;100942Turk MA, Landes SD, Formica MK, Goss KD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473875>
9. **The Mental Health Consequences of COVID-19 pandemic in Dentistry.** *Disaster Med Public Health Prep* 2020;1-13Vergara-Buenaventura A, Chavez-Tunon M, Castro-Ruiz C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498741>
10. **[Mental health care in French correctional facilities during the Covid-19 pandemic].** *Encephale* 2020; Fovet T, Lancelevee C, Eck M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475693>
11. **[The effects of quarantine for SARS-CoV-2 on sleep: An online survey].** *Encephale* 2020; Hartley S, Colas des Francs C, Aussert F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475692>
12. **The social psychological impact of the COVID-19 epidemic on medical staff in China: a cross-sectional study.** *Eur. Psychiatry* 2020;1-22Dong ZQ, Ma J, Hao YN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476633>
13. **Mental health among otolaryngology resident and attending physicians during the COVID-19 pandemic: National study.** *Head Neck* 2020; Civantos AM, Byrnes Y, Chang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496637>
14. **Rural Health, Behavioral Health, And More.** *Health Aff (Millwood)* 2020; 39:919-920Weil AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479231>
15. **[Exploring the Stress, Psychological Distress, and Stress-relief Strategies of Taiwan Nursing Staffs Facing the Global Outbreak of COVID-19].** *Hu Li Za Zhi* 2020; 67:64-74Feng MC, Wu HC, Lin HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495331>
16. **Breast Cancer and COVID-19: The Effect of Fear on Patients' Decision-making Process.** *In Vivo* 2020; 34:1651-1659Vanni G, Materazzo M, Pellicciario M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503825>
17. **Related Health Factors of Psychological Distress During the COVID-19 Pandemic in Spain.** *Int J Environ Res Public Health* 2020; 17Gomez-Salgado J, Andres-Villas M, Dominguez-Salas S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498401>
18. **Coping with COVID-19: Exposure to COVID-19 and Negative Impact on Livelihood Predict Elevated Mental Health Problems in Chinese Adults.** *Int J Environ Res Public Health* 2020; 17Guo J, Feng XL, Wang XH, van IMH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485859>
19. **Distress and Resilience in the Days of COVID-19: Comparing Two Ethnicities.** *Int J Environ Res Public Health* 2020; 17Kimhi S, Eshel Y, Marciano H, Adini B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503205>
20. **The Impact of COVID-19 on Physical Activity Behavior and Well-Being of Canadians.** *Int J Environ Res Public Health* 2020; 17Lesser IA, Nienhuis CP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486380>
21. **The Psychological Impacts of a COVID-19 Outbreak on College Students in China: A Longitudinal Study.** *Int J Environ Res Public Health* 2020; 17Li HY, Cao H, Leung DYP, Mak YW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498267>
22. **COVID-19 Emergence and Social and Health Determinants in Colorado: A Rapid Spatial Analysis.** *Int J Environ Res Public Health* 2020; 17Ramirez IJ, Lee J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485854>
23. **Psychological impact of COVID-19 quarantine measures in northeastern Italy on mothers in the immediate postpartum period.** *Int J Gynaecol Obstet* 2020; Zanardo V, Manghina V, Giliberti L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474910>
24. **Social consequences of COVID-19 in a low resource setting in Sierra Leone, West Africa.** *Int J Infect Dis* 2020; Buonsenso D, Cinicola B, Raffaelli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497794>
25. **Emergency mental health legislation in response to the Covid-19 (Coronavirus) pandemic in Ireland: Urgency, necessity and proportionality.** *Int. J. Law Psychiatry* 2020; 70:101564Kelly BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482306>
26. **The psychosocial effects of being quarantined following exposure to COVID-19: A qualitative study of Lebanese health care workers.** *Int J Soc Psychiatry* 2020;20764020932202Fawaz M, Samaha A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489149>
27. **COVID-19 quarantine: Post-traumatic stress symptomatology among Lebanese citizens.** *Int J Soc Psychiatry* 2020;20764020932207Fawaz M, Samaha A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489136>
28. **Mental health of older adults during the COVID-19 pandemic: lessons from history to guide our future.** *Int. Psychogeriatr.* 2020;1-4Chong TWH, Curran E, Ames D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489166>
29. **Mental Health and the COVID19 Pandemic.** *Ir. J. Psychol. Med.* 2020;1-7Gavin B, Lyne J, McNicholas F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475368>
30. **Could COVID-19 improve psychiatric awareness at the heart of the Middle East? - A personal reflection on Bahrain's response.** *Ir. J. Psychol. Med.* 2020;1-8Maher Negm H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484123>
31. **Adolescents' Motivations to Engage in Social Distancing During the COVID-19 Pandemic: Associations With Mental and Social Health.** *J. Adolesc. Health* 2020; Oosterhoff B, Palmer CA, Wilson J, Shook N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487491>
32. **COVID-19: Implications for the Support of People with Social Care Needs in England.** *J Aging Soc Policy* 2020;1-8Comas-Herrera A, Fernandez JL, Hancock R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497462>
33. **The Unique Challenges Faced by Assisted Living Communities to Meet Federal Guidelines for COVID-19.** *J Aging Soc Policy* 2020;1-9Dobbs D, Peterson L, Hyer K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496899>
34. **Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of COVID-19.** *J. Am. Acad. Child Adolesc. Psychiatry* 2020; Loades ME, Chatburn E, Higson-Sweeney N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504808>
35. **Health anxiety, cyberchondria, and coping in the current COVID-19 pandemic: Which factors are related to coronavirus anxiety?** *J. Anxiety Disord.* 2020; 73:102239Jungmann SM, Witthoft M.



- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502806>
36. **Managing uncertainty during a global pandemic: An international business perspective.** *J Bus Res* 2020; 116:188-192 Sharma P, Leung TY, Kingshott RPJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501304>
  37. **Social-economic impact of COVID-19 pandemic on aesthetic centers in Greece.** *J Cosmet Dermatol* 2020; Biskanaki F, Rallis E, Andreou E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475018>
  38. **The potential impact of vulnerability and coping capacity on the pandemic control of COVID-19.** *J Infect* 2020; Wong MC, Teoh JY, Huang J, Wong SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474040>
  39. **A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.** *J Med Virol* 2020; Zhang Z, Wang S, Tu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501538>
  40. **A review of pathophysiology and neuropsychiatric manifestations of COVID-19.** *J Neurol* 2020; Jasti M, Nalleballe K, Dandu V, Onteddu S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494854>
  41. **Syndemic frameworks to understand the effects of COVID-19 on commercial driver stress, health, and safety.** *J Transp Health* 2020; 18:100877 Lemke MK, Apostolopoulos Y, Sonmez S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501420>
  42. **The impact of the Covid-19 pandemic on domestic violence: The dark side of home isolation during quarantine.** *Med. Leg. J.* 2020:25817220930553 Sacco MA, Caputo F, Ricci P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501175>
  43. **Psychological support and psychotherapy via digital devices in Covid-19 emergency time: Some critical issues.** *Med. Leg. J.* 2020:25817220926942 Tullio V, Perrone G, Bilotta C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490713>
  44. **What has Covid-19 taken from us and brought instead?** *Oral Dis* 2020; Buduneli N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474987>
  45. **Dysfunctional personality features, non-scientifically supported causal beliefs, and emotional problems during the first month of the COVID-19 pandemic in Italy.** *Pers. Individ. Dif.* 2020; 165:110139 Somma A, Gialdi G, Krueger RF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501318>
  46. **Schizophrenia and COVID-19 delirium.** *Psychiatry Res* 2020; 290:113137 Palomar-Ciria N, Blanco Del Valle P, Hernandez-Las Heras MA, Martinez-Gallardo R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485483>
  47. **The impacts of vulnerability, perceived risk, and fear on preventive behaviours against COVID-19.** *Psychol Health Med* 2020:1-9 Yildirim M, Gecer E, Akgul O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490689>
  48. **On the clinical psychologist's role in the time of COVID-19, with particular reference to experience gained in pediatric oncology.** *Psychooncology* 2020; Clerici CA, Massimino M, Ferrari A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501640>
  49. **COVID-19 and Intimate Partner Violence: A Call to Action.** *R I Med J (2013)* 2020; 103:57-59 Zero O, Geary M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32481784>
  50. **The psychological impact of COVID-19 pandemic on physicians in Saudi Arabia: A cross-sectional study.** *Saudi J. Gastroenterol.* 2020; Al Sulais E, Mosli M, AlAmeel T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496223>
  51. **The impact of COVID-19 on individuals living with serious mental illness.** *Schizophr Res* 2020; Hamada K, Fan X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473931>
  52. **The evaluation of sleep disturbances for Chinese frontline medical workers under the outbreak of COVID-19.** *Sleep Med.* 2020; 72:1-4 Qi J, Xu J, Li BZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502844>
  53. **Perceived stress and sleep quality among the non-diseased general public in China during the 2019 coronavirus disease: a moderated mediation model.** *Sleep Med.* 2020; Zhao X, Lan M, Li H, Yang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482485>
  54. **[Consideration on improving public health emergency management ability of current medical health system].** *Zhonghua Liu Xing Bing Xue Za Zhi* 2020; 41:E072 Cao GW, Zhang BX, Chen XP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498493>

## Meta-analyses - systematic reviews (8 articles)

1. **Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis.** *Aging Dis* 2020; 11:668-678 Liu H, Chen S, Liu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489711>
2. **Systematic Review and Meta-Analysis on the Value of Chest CT in the Diagnosis of Coronavirus Disease (COVID-19): Sol Scientiae, Illustra Nos.** *AJR Am J Roentgenol* 2020:1-9 Adams HJA, Kwee TC, Yakar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478562>
3. **Drinking no-links to the severity of COVID-19: a systematic review and meta-analysis.** *J Infect* 2020; Liu M, Gao Y, Shi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474047>
4. **The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis.** *J Infect* 2020; Liu M, Gao Y, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502509>
5. **Estimation of RAAS-Inhibitor effect on the COVID-19 outcome: A Meta-analysis.** *J Infect* 2020; Pirola CJ, Sookoian S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474043>
6. **Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.** *J Intensive Care* 2020; 8:36 Huang I, Pranata R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483488>
7. **Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis.** *J Med Virol* 2020; Aikawa T, Takagi H, Ishikawa K, Kuno T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484975>
8. **Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis.** *Rev Med Virol* 2020:e2112 Pormohammad A, Ghorbani S, Khatami A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502331>

## Mortality (10 articles)

1. **COVID-19, economic impact and child mortality: A global concern.** *Clin. Nutr.* 2020; Kabir M, Saqib MAN, Zaid M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499056>
2. **A fatal case of COVID-19 due to metabolic acidosis following dysregulate inflammatory response (cytokine storm).** *IDCases* 2020; 21:e00829Chhetri S, Khamis F, Pandak N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483525>
3. **Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany.** *Int. J. Legal Med.* 2020; Edler C, Schroder AS, Aepfelbacher M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500199>
4. **Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation.** *Int. J. Legal Med.* 2020; Suess C, Hausmann R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504146>
5. **Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico.** *J. Clin. Endocrinol. Metab.* 2020; Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474598>
6. **Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury.** *J Clin Med* 2020; 9Lim JH, Park SH, Jeon Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503180>
7. **Estimating the Risk of COVID-19 Death During the Course of the Outbreak in Korea, February-May 2020.** *J Clin Med* 2020; 9Shim E, Mizumoto K, Choi W, Chowell G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485871>
8. **Dead body management amidst global pandemic of Covid-19.** *Med. Leg. J.* 2020:25817220926930Vidua RK, Duskova I, Bhargava DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501134>
9. **Role of a habitat's air humidity in Covid-19 mortality.** *Sci Total Environ* 2020; 736:138763Biktasheva IV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492610>
10. **[Thoughts and suggestions on analysis of death cases report during COVID-19 epidemic].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:1531-1535Li B, Yan YM, Li ZY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489031>

## On-line – IT – Apps (31 articles)

1. **Private metropolitan telepsychiatry in Australia during Covid-19: current practice and future developments.** *Australas Psychiatry* 2020:1039856220930675Looi JC, Pring W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484737>
2. **Telemedicine as a tool for PrEP delivery during the COVID-19 pandemic in a large HIV prevention service in Rio de Janeiro-Brazil.** *Braz. J. Infect. Dis.* 2020; Hoagland B, Torres TS, Bezerra DRB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504552>
3. **Feasibility and Preliminary Results of Effectiveness of Social Media-based Intervention on the Psychological Well-being of Suspected COVID-19 Cases during Quarantine.** *Can. J. Psychiatry.* 2020:706743720932041Zhou L, Xie RH, Yang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483978>
4. **Switching to teleconsultation for rheumatology in the wake of the COVID-19 pandemic: feasibility and patient response in India.** *Clin Rheumatol* 2020; Shenoy P, Ahmed S, Paul A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474883>
5. **COVID-19 and applications of smartphone technology in the current pandemic.** *Diabetes Metab Syndr* 2020; 14:733-737Iyengar K, Upadhyaya GK, Vaishya R, Jain V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497963>
6. **Coronavirus Disease (COVID-19): A Machine Learning Bibliometric Analysis.** *In Vivo* 2020; 34:1613-1617F DEF, Polimeni A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503819>
7. **An overview of mobile applications (apps) to support the coronavirus disease-2019 response in India.** *Indian J Med Res* 2020; Bassi A, Arfin S, John O, Jha V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474557>
8. **Factors affecting the adoption of telemedicine during COVID-19.** *Indian J. Public Health* 2020; 64:S234-s236Mishra V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496263>
9. **A modified deep convolutional neural network for detecting COVID-19 and pneumonia from chest X-ray images based on the concatenation of Xception and ResNet50V2.** *Inform Med Unlocked* 2020; 19:100360Rahimzadeh M, Attar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501424>
10. **A Visual Approach for the SARS (Severe Acute Respiratory Syndrome) Outbreak Data Analysis.** *Int J Environ Res Public Health* 2020; 17Hua J, Wang G, Huang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503333>
11. **Robotics Utilization for Healthcare Digitization in Global COVID-19 Management.** *Int J Environ Res Public Health* 2020; 17Khan ZH, Siddique A, Lee CW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32481547>
12. **Management strategies and role of telemedicine in a Surgery Unit during COVID-19 outbreak.** *Int J Surg* 2020; Palomba G, Dinuzzi VP, Aprea G, De Palma GD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479914>
13. **Effectively Engaging Geriatric Patients via Tele dermatology.** *J Am Acad Dermatol* 2020; Simpson CL, Kovarik CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497703>
14. **Rapid Deployment of Inpatient Telemedicine In Response to COVID-19 Across Three Health Systems.** *J Am Med Inform Assoc* 2020; Vilendrer S, Patel B, Chadwick W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495830>
15. **Using Machine Learning to Predict ICU Transfer in Hospitalized COVID-19 Patients.** *J Clin Med* 2020; 9Cheng FY, Joshi H, Tandon P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492874>
16. **COVID-19 Awakens a New Focus on Surge Capacity Blood Glucose Testing and the Critical Role of Telehealth in Self-Management.** *J. Diabetes Sci. Technol.* 2020:1932296820930035Fantz CR, Rivers M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486964>

17. **COVID-19 and Diabetes: Could Diabetes Technology Research Help Pave the Way for Remote Healthcare?** *J. Diabetes Sci. Technol.* 2020:1932296820929714Fuchs J, Hovorka R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475169>
18. **COVID-19 Pandemic Triggers Telemedicine Regulation and Intensifies Diabetes Management Technology Adoption in Brazil.** *J. Diabetes Sci. Technol.* 2020:1932296820930033Teles M, Sacchetta T, Matsumoto Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482098>
19. **Learning From COVID-19 and Looking to Technology Ahead.** *J. Diabetes Sci. Technol.* 2020:1932296820930280Toft AD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482092>
20. **COVID-19-Related Information Sources and the Relationship With Confidence in People Coping with COVID-19: Facebook Survey Study in Taiwan.** *J Med Internet Res* 2020; 22:e20021Wang PW, Lu WH, Ko NY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490839>
21. **National outreach of telepalliative medicine volunteers for a New York City safety net system COVID-19 pandemic response.** *J Pain Symptom Manage* 2020; Israilov S, Krouss M, Zaurova M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479861>
22. **Pharmacist intervention amid the coronavirus disease 2019 (COVID-19) pandemic: from direct patient care to telemedicine.** *J Pharm Policy Pract* 2020; 13:23Elbeddini A, Yeats A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501410>
23. **Impact of Rumors and Misinformation on COVID-19 in Social Media.** *J Prev Med Public Health* 2020; 53:171-174Tasnim S, Hossain MM, Mazumder H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498140>
24. **Telemedicine during Covid-19 pandemic: Advantage or critical issue?** *Med. Leg. J.* 2020:25817220926926Perrone G, Zerbo S, Bilotta C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490720>
25. **Family doctor-centered care: Continuous monitoring of COVID-19 patients - New software module.** *MMW-Fortschritte der Medizin* 2020; 162:35fst.
26. **Predicting COVID-19 Incidence Using Anosmia and Other COVID-19 Symptomatology: Preliminary Analysis Using Google and Twitter.** *Otolaryngol Head Neck Surg* 2020:194599820932128Panuganti BA, Jafari A, MacDonald B, DeConde AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484425>
27. **Telemedicine and the Interdisciplinary Clinic Model: During the COVID-19 Pandemic and Beyond.** *Otolaryngol Head Neck Surg* 2020:194599820932167Zughni LA, Gillespie AI, Hatcher JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484731>
28. **Usefulness of a Telemedicine Tool TELEA in the Management of the COVID-19 Pandemic.** *Telemed J E Health* 2020; Rabunal R, Suarez-Gil R, Golpe R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501747>
29. **Tele-oncology in the COVID-19 Era: The Way Forward?** *Trends Cancer* 2020; Shirke MM, Shaikh SA, Harky A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487487>
30. **A short, animated video to improve good COVID-19 hygiene practices: a structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:469Vandormael A, Adam M, Greuel M, Barnighausen T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493460>
31. **Virtual Spine: A novel, international teleconferencing program developed to increase the accessibility of spine education during the COVID-19 pandemic.** *World Neurosurg* 2020; Rasouli JJ, Shin JH, Than KD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474104>

## Other – Miscellaneous (34 articles)

1. **[Medical Professionalism and the Social Contract: Reflections on the COVID-19 Pandemic].** *Acta Med Port* 2020; 33:362-364Ferreira MA, Carvalho Filho MA, Franco GS, Franco RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504510>
2. **Home delivery of medication during Coronavirus disease 2019, Cape Town, South Africa: Short report.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e4Brey Z, Mash R, Goliath C, Roman D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501022>
3. **COVID-19, Prison Visits, and the Value of a Cup of Coffee.** *Ann Intern Med* 2020; Doyle TJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479164>
4. **21-Day Lockdown in India Dramatically Reduced Air Pollution Indices in Lucknow and New Delhi, India.** *Bull. Environ. Contam. Toxicol.* 2020; Srivastava S, Kumar A, Baudh K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495123>
5. **The impact of COVID-19 pandemic upon stability and sequential irregularity of equity and cryptocurrency markets.** *Chaos Solitons Fractals* 2020; 138:109936Lahmiri S, Bekiros S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501379>
6. **Tuberculosis Healthcare Workers: There Goes My Hero.** *Clin Infect Dis* 2020; Griffith DE, Cegielski JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502233>
7. **Historical evidence for economic effects of COVID-19.** *Eur J Health Econ* 2020; Ceylan RF, Ozkan B, Mulazimogullari E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500243>
8. **Community Health Workers And COVID-19.** *Health Aff (Millwood)* 2020; 39:1097Hansmann KJ, Kind AJH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479233>
9. **Community Health Workers: The Authors Reply.** *Health Aff (Millwood)* 2020; 39:1097Kangovi S, Asch DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479214>
10. **Risk-Informed Decision Making: More Critical Today Than Ever Before.** *Health Secur* 2020; Watson C, Mullen L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497443>
11. **Knowledge, attitude, and practices related to COVID-19 pandemic among social media users in J&K, India.** *Indian J. Public Health* 2020; 64:S205-s210Dkhar SA, Quansar R, Saleem SM, Khan SMS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496256>
12. **Concerns of Frontline Doctors in India during COVID-19: A Cross-Sectional Survey.** *Indian J. Public Health* 2020; 64:S237-s239Singh H, Sharma S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496264>
13. **"Not Wars, Water pumps" - From emotive to rational language in managing the Covid-19 pandemic.** *Int J Clin Pract* 2020; Stedman M, Davies M, Heald A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502319>
14. **Crafting Jobs for Occupational Satisfaction and Innovation among Manufacturing Workers Facing the COVID-19 Crisis.** *Int J Environ Res Public Health* 2020; 17Ren T, Cao L, Chin T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503169>



15. **COVID-19 and fiscal space for health system in Pakistan: It is time for a policy decision.** *Int. J. Health Plann. Manage.* 2020; Shaikh BT, Ali N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476158>
16. **Employee adjustment and well-being in the era of COVID-19: Implications for human resource management.** *J Bus Res* 2020; 116:183-187Carnevale JB, Hatak I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501303>
17. **Masters of disasters? Challenges and opportunities for SMEs in times of crisis.** *J Bus Res* 2020; 116:199-208Eggers F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501306>
18. **Gender equity and public health outcomes: The COVID-19 experience.** *J Bus Res* 2020; 116:193-198Leung TY, Sharma P, Adithipyangkul P, Hosie P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501305>
19. **Competing during a pandemic? Retailers' ups and downs during the COVID-19 outbreak.** *J Bus Res* 2020; 116:209-213Pantano E, Pizzi G, Scarpi D, Dennis C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501307>
20. **Marketing innovations during a global crisis: A study of China firms' response to COVID-19.** *J Bus Res* 2020; 116:214-220Wang Y, Hong A, Li X, Gao J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501308>
21. **A Pandemic Forces United States to Leap Forward.** *J. Diabetes Sci. Technol.* 2020:1932296820929412Argento NB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486843>
22. **Risk Perception of COVID-19 Among the Portuguese Healthcare Professionals and General Population.** *J Hosp Infect* 2020; Peres D, Monteiro J, Almeida M, Ladeira R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485198>
23. **We Are the First to Applaud You Regarding Your Efforts in COVID-19: A Message from the African Diaspora to Our Brothers and Sisters of Africa.** *J Racial Ethn Health Disparities* 2020; Laurencin CT, McClinton A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500388>
24. **COVID-19 and picotechnology: Potential opportunities.** *Med. Hypotheses* 2020; 144:109917Rabiee N, Rabiee M, Bagherzadeh M, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32505072>
25. **Is Covid-19 sowing the seeds for future litigation?** *Med. Leg. J.* 2020:25817220926943Riley-Smith Qc T, Heppinstall A, Foster F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490743>
26. **Ethical Framework for Nutrition Support Resource Allocation During Shortages: Lessons From COVID-19.** *Nutr. Clin. Pract.* 2020; Barrocas A, Schwartz DB, Hasse JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492759>
27. **Effects of COVID-19 Home Confinement on Eating Behaviour and Physical Activity: Results of the ECLB-COVID19 International Online Survey.** *Nutrients* 2020; 12Ammar A, Brach M, Trabelsi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32481594>
28. **Dietary Choices and Habits during COVID-19 Lockdown: Experience from Poland.** *Nutrients* 2020; 12Sidor A, Rzymiski P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503173>
29. **Food Insecurity and COVID-19: Disparities in Early Effects for US Adults.** *Nutrients* 2020; 12Wolfson JA, Leung CW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498323>
30. **Impact of COVID-19 outbreak measures of lockdown on the Italian Carbon Footprint.** *Sci Total Environ* 2020; 737:139806Rugani B, Caro D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492608>
31. **Increased ozone levels during the COVID-19 lockdown: Analysis for the city of Rio de Janeiro, Brazil.** *Sci Total Environ* 2020; 737:139765Siciliano B, Dantas G, da Silva CM, Arbilla G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480061>
32. **Dwindling blood reserves: An ominous downside of COVID-19 pandemic.** *Transfus. Apher. Sci.* 2020:102818Kumar S, Azim D, Nasim S, Hashmi SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487511>
33. **How can physicians advise faith communities during the COVID-19 pandemic?** *Travel Med Infect Dis* 2020:101762Merry SP, Havyer RD, McCoy RG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497766>
34. **[Thoughts and suggestions on arrangement, analysis and summary of medical data during COVID-19 epidemic].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:1526-1530Yan YM, Li B, Li ZY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489030>

## Pathology (9 articles)

1. **Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2.** *Curr. Protoc. Microbiol.* 2020; 57:ecpmc105Mendoza EJ, Manguiat K, Wood H, Drebot M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475066>
2. **The craniotomy box: an innovative method of containing hazardous aerosols generated during skull saw use in autopsy on a COVID-19 body.** *Forensic Sci. Med. Pathol.* 2020; Hasmi AH, Khoo LS, Koo ZP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500339>
3. **Guide to forensic pathology practice for death cases related to coronavirus disease 2019 (COVID-19) (Trial draft).** *Forensic Sci Res* 2020; 5:1-7Mao D, Zhou N, Zheng D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490304>
4. **Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany.** *Int. J. Legal Med.* 2020; Edler C, Schroder AS, Aepfelbacher M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500199>
5. **Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation.** *Int. J. Legal Med.* 2020; Suess C, Hausmann R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504146>
6. **Dermatopathology Education During the COVID-19 Pandemic: Virtual Simulation of the Multi-Headed Microscope.** *J Am Acad Dermatol* 2020; Kim RH, Brinster NK, Meehan SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497706>
7. **Histology of skin lesions establishes that the vesicular rash associated with COVID-19 is not "varicella-like".** *J Eur Acad Dermatol Venereol* 2020; Mahe A, Birckel E, Merklen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500642>
8. **Clinical and histological characterization of late appearance maculopapular eruptions in association with the coronavirus disease 2019. A case series of seven patients.** *J Eur Acad Dermatol Venereol* 2020; Reymundo A, Fernandez-Bernaldez A, Reolid A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495368>
9. **An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies.** *Travel Med Infect Dis* 2020:101755Dhama

## Protection (46 articles)

1. **Securing Posterior Auricular Incision with Button Headbands in Prominent Ear Patients Wearing Surgical Masks for Self-protection in the Pandemic.** *Aesthetic Plast. Surg.* 2020; Ozkan B, Uysal CA, Ertas NM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500322>
2. **Primary healthcare practitioners and patient blood management in Africa in the time of coronavirus disease 2019: Safeguarding the blood supply.** *Afr J Prim Health Care Fam Med* 2020; 12:e1-e3Barrett CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501018>
3. **Respiratory protection for health care workers: A 2020 COVID-19 perspective.** *Am. J. Ind. Med.* 2020; Petsonk EL, Harber P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496602>
4. **Environmental contamination of SARS-CoV-2 during the COVID-19 outbreak in South Korea.** *Am. J. Infect. Control* 2020; Ryu BH, Cho Y, Cho OH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485273>
5. **Gastrointestinal endoscopy operation--A potential transmission risk for SARS-CoV-2.** *Am. J. Infect. Control* 2020; Tan C, Xiao Y, Wu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485277>
6. **Decontamination of Surgical Face Masks and N95 Respirators by Dry Heat Pasteurization for One Hour at 70 degrees C.** *Am. J. Infect. Control* 2020; Xiang Y, Song Q, Gu W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479844>
7. **"Hot Zones" for Otolaryngologists: Assessing the geographic distribution of aerosol-generating procedures amidst the COVID-19 pandemic.** *Am. J. Otolaryngol.* 2020; 41:102550Quereshy HA, Jella TK, Ruthberg JS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485299>
8. **Notice of Retraction: Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2.** *Ann Intern Med* 2020; Bae S, Kim MC, Kim JY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479106>
9. **Protecting staff and patients during airway management in the COVID-19 pandemic: are intubation boxes safe?** *Br J Anaesth* 2020; Gould CL, Alexander PDG, Allen CN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473727>
10. **COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities.** *Clin Chim Acta* 2020; Lotfi M, Hamblin MR, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474009>
11. **Practical Guidelines for Collection, Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens.** *Curr Protoc Cytom* 2020; 93:e77Bain W, Lee JS, Watson AM, Stitt-Fischer MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502333>
12. **Protection comes at a cost: Doctor's life inside Personal Protection Equipment.** *Dermatol Ther* 2020:e13758Bhargava S, Gupta M, Kroumpouzou G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495994>
13. **Laser Safety Measures for The Treatment of Genital Warts in Hiv+ Patients During The Covid-19 Pandemic.** *Dermatol Ther* 2020:e13750Cameli N, Mariano M, Latini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495468>
14. **Topical rh-aFGF: An effective therapeutic agent for facemask wearing-induced pressure sores.** *Dermatol Ther* 2020:e13745Luo P, Liu D, Li J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478959>
15. **Safeguarding Dermatologist Attendings and Residents Amid the COVID-19 Pandemic: Focus on Special Populations.** *Dermatol Ther* 2020:e13749Stewart CR, Lipner SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495403>
16. **Effectiveness of N95 Respirator Decontamination and Reuse against SARS-CoV-2 Virus.** *Emerg Infect Dis* 2020; 26Fischer RJ, Morris DH, van Doremalen N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491983>
17. **SARS-CoV-2 RNA Detection on Disposable Wooden Chopsticks, Hong Kong.** *Emerg Infect Dis* 2020; 26Lui G, Lai CKC, Chen Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491982>
18. **Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.** *Emerg Infect Dis* 2020; 26Ryu S, Ali ST, Jang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487283>
19. **How and why use the EasyBreath(R) Decathlon surface snorkeling mask as a personal protective equipment during the COVID-19 pandemic?** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Thierry B, Celerier C, Simon F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493648>
20. **Endoscopic nasopharyngoscopy and ENT specialist safety in the COVID 19 era: the back endoscopy approach to the patient.** *Eur Arch Otorhinolaryngol* 2020; Di Maio P, Traverso D, Iocca O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500327>
21. **The craniotomy box: an innovative method of containing hazardous aerosols generated during skull saw use in autopsy on a COVID-19 body.** *Forensic Sci. Med. Pathol.* 2020; Hasmi AH, Khoo LS, Koo ZP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500339>
22. **Acidified Sodium Chlorite Solution: A Potential Prophylaxis to Mitigate Impact of Multiple Exposures to COVID-19 in Frontline Healthcare Providers.** *Hosp Pract (1995)* 2020; Karnik-Henry MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497459>
23. **Facemasks for prevention of viral respiratory infections in community settings: A systematic review and meta-analysis.** *Indian J. Public Health* 2020; 64:S192-s200Aggarwal N, Dwarakanathan V, Gautam N, Ray A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496254>
24. **Rational use of face mask in a tertiary care hospital setting during COVID-19 pandemic: An observational study.** *Indian J. Public Health* 2020; 64:S225-s227Supehia S, Singh V, Sharma T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496260>
25. **HUMAN CORONAVIRUS DATA FROM FOUR CLINICAL TRIALS OF MASKS AND RESPIRATORS.** *Int J Infect Dis* 2020; MacIntyre CR, Chughtai AA, Seale H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497810>
26. **A Potential Hidden Reservoir: The Role of Nail Hygiene in Preventing Transmission of COVID-19.** *J Am Acad Dermatol* 2020; Wu AG, Lipner SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497691>
27. **ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak: Endorsed by the American College of Cardiology.** *J. Am. Soc. Echocardiogr.* 2020; 33:648-653Kirkpatrick JN, Mitchell C, Taub C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503700>

28. **Specific Considerations for Sonographers When Performing Echocardiography during the 2019 Novel Coronavirus Outbreak: Supplement to the American Society of Echocardiography Statement.** *J. Am. Soc. Echocardiogr.* 2020; 33:654-657 Mitchell C, Collins K, Hua L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503701>
29. **Specific Considerations for the Protection of Patients and Echocardiography Service Providers When Performing Perioperative or Periprocedural Transesophageal Echocardiography during the 2019 Novel Coronavirus Outbreak: Council on Perioperative Echocardiography Supplement to the Statement of the American Society of Echocardiography Endorsed by the Society of Cardiovascular Anesthesiologists.** *J. Am. Soc. Echocardiogr.* 2020; 33:666-669 Nicoara A, Maldonado Y, Kort S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503703>
30. **A modified barrier enclosure to prevent viral aerosol transmission during endotracheal intubation and extubation of patients with coronavirus disease.** *J. Clin. Anesth.* 2020; 65:109876 Kojima Y, Aoyama K, Yamagata K, Sugimura M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502759>
31. **Retroauricular dermatitis with vehement use of ear loop face masks during COVID19 pandemic.** *J Eur Acad Dermatol Venereol* 2020; Bothra A, Das S, Singh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491204>
32. **Hand Eczema Pandemic Caused by SARS-CoV-2 Hygiene Measures: The Setup of a Hand Eczema Helpline for Hospital Personnel.** *J Eur Acad Dermatol Venereol* 2020; Greveling K, Kunkeler ACM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488925>
33. **High SARS-CoV-2 Antibody Prevalence among Healthcare Workers Exposed to COVID-19 Patients.** *J Infect* 2020; Chen Y, Tong X, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504745>
34. **Temperature-dependent surface stability of SARS-CoV-2.** *J Infect* 2020; Kratzel A, Steiner S, Todt D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504748>
35. **SARS, MERS and COVID-19 among healthcare workers: A narrative review.** *J Infect Public Health* 2020; Xiao J, Fang M, Chen Q, He B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493671>
36. **Guidance for otolaryngology health care workers performing aerosol generating medical procedures during the COVID-19 pandemic.** *J. Otolaryngol. Head Neck Surg.* 2020; 49:36 Lammers MJW, Lea J, Westerberg BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493489>
37. **COVID-19 and veterinarians for one health, zoonotic- and reverse-zoonotic transmissions.** *J. Vet. Sci.* 2020; 21:e51 Yoo HS, Yoo D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476324>
38. **Airborne Spread of SARS-CoV-2 and a Potential Role for Air Disinfection.** *JAMA* 2020; Nardell EA, Nathavitharana RR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478797>
39. **Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.** *Med. Hypotheses* 2020; 144:109910 Caruso AA, Del Prete A, Lazzarino AI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32505069>
40. **Dead body management amidst global pandemic of Covid-19.** *Med. Leg. J.* 2020; 258:17220926930 Vidua RK, Duskova I, Bhargava DC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501134>
41. **Oral saliva and COVID-19.** *Oral Oncol* 2020; 108:104821 Baghizadeh Fini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474389>
42. **Rhinologic Practice Special Considerations During COVID-19: Visit Planning, Personal Protective Equipment, Testing, and Environmental Controls.** *Otolaryngol Head Neck Surg* 2020; 194:599820933169 Howard BE, Lal D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484728>
43. **SARS-CoV-2 Infection in Health Care Workers: Cross-sectional Analysis of an Otolaryngology Unit.** *Otolaryngol Head Neck Surg* 2020; 194:599820932162 Paderno A, Fior M, Berretti G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482123>
44. **A short, animated video to improve good COVID-19 hygiene practices: a structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:469 Vandormael A, Adam M, Greuel M, Barnighausen T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493460>
45. **[Surgery during the SARS-CoV-2 pandemic : Recommendations on operative procedures].** *Unfallchirurg* 2020; Mahlke L, Flohe S, Matthes G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488319>
46. **Surgical precautions for Urologists in the era of COVID-19.** *Urology* 2020; Chan MC, Kwok JL, Yeo SEK, Chong YL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504680>

## Pulmonary disease (10 articles)

1. **Respiratory Mechanics of COVID-19 vs. Non-COVID-19 Associated Acute Respiratory Distress Syndrome.** *Am J Respir Crit Care Med* 2020; Haudebourg AF, Perier F, Tuffet S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479162>
2. **A Comprehensive Review of Severe Acute Respiratory Syndrome Coronavirus 2.** *Cureus* 2020; 12:e7943 Baek WK, Sohn SY, Mahgoub A, Hage R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499983>
3. **Refractory Acute Respiratory Distress Syndrome Secondary to COVID-19 Successfully Extubated to Average Volume-assured Pressure Support Non-invasive Ventilator.** *Cureus* 2020; 12:e7849 Mittal A, Forte M, Leonard R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483500>
4. **Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report.** *J Am Coll Radiol* 2020; Mazzone PJ, Gould MK, Arenberg DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485147>
5. **Outcomes of COVID-19 among Patients on In-Center Hemodialysis: An Experience from the Epicenter in South Korea.** *J Clin Med* 2020; 9: Jung HY, Lim JH, Kang SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498262>
6. **Inpatient Management of COVID-19 Pneumonia: a Practical Approach from the Hospitalist Perspective.** *J Gen Intern Med* 2020; Cutler TS, Eisenberg N, Evans AT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500328>
7. **COVID-19 and Acute Lupus Pneumonitis: Diagnostic and Treatment Dilemma.** *J Investig Med High Impact Case Rep* 2020; 8:2324709620933438 Kichloo A, Aljadah M, Albosta M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500773>
8. **Chronic obstructive pulmonary disease and the COVID-19 pandemic: Reciprocal challenges.** *Respir Med Res* 2020; 78:100764 Deslee G, Zysman M, Burgel PR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500773>



term=32498023

9. **Radiology of COVID-19 Pneumonia - Pictorial Essay and Structured Reporting.** *RoFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin* 2020; 192:513-517 Schaible J, Meiler S, Poschenrieder F *et al.*
10. **[Application of Reyanning Mixture in evaluating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:1465-1472 Bao L, Shi YJ, Geng ZH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489022>

## Renal disease (8 articles)

1. **Kidney Infarction in Patients With COVID-19.** *Am J Kidney Dis* 2020; Post A, den Deurwaarder ESG, Bakker SJL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479921>
2. **Disaster Response to the COVID-19 Pandemic for Patients with Kidney Disease in New York City.** *J Am Soc Nephrol* 2020. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499395>
3. **Hemodialysis with Cohort Isolation to Prevent Secondary Transmission during a COVID-19 Outbreak in Korea.** *J Am Soc Nephrol* 2020; Cho JH, Kang SH, Park HC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482688>
4. **Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury.** *J Clin Med* 2020; 9Lim JH, Park SH, Jeon Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503180>
5. **COVID-19 and Renal Failure: Challenges in the Delivery of Renal Replacement Therapy.** *J. Clin. Med. Res.* 2020; 12:276-285 Adapa S, Aeddula NR, Konala VM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489502>
6. **COVID-19 and kidney transplantation: an Italian Survey and Consensus.** *J Nephrol* 2020; Vistoli F, Furian L, Maggiore U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495231>
7. **Review of the present features and the infection control challenges of COVID-19 pandemic in dialysis facilities.** *Kaohsiung J. Med. Sci.* 2020; Lee JJ, Hwang SJ, Huang JF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492290>
8. **Renal Monomorphology in COVID-19 with Acute Renal Insufficiency.** *Praxis* 2020:1-5 Tuma J, Neugebauer F, Rohacek M, Serra A.

## Reviews (33 articles)

1. **Coronavirus Disease 2019: Clinical Review.** *Acta Med Port* 2020; Gouveia CC, Campos L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498762>
2. **Dysfunctional Coagulation in COVID-19: From Cell to Bedside.** *Adv Ther* 2020; Wang J, Saguner AM, An J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504450>
3. **Cholesterol: A new game player accelerating endothelial injuries caused by SARS-CoV-2?** *Am J Physiol Endocrinol Metab* 2020; Cao X, Yin R, Albrecht H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501731>
4. **Understanding the age divide in COVID-19: Why are children overwhelmingly spared?** *Am J Physiol Lung Cell Mol Physiol* 2020; Lingappan K, Karmouty-Quintana H, Davies J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491949>
5. **A Comprehensive Review of Severe Acute Respiratory Syndrome Coronavirus 2.** *Cureus* 2020; 12:e7943 Baek WK, Sohn SY, Mahgoub A, Hage R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499983>
6. **Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.** *Cureus* 2020; 12:e8342 Bhagavathula AS, Aldhaleei WA, Rovetta A, Rahmani J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494546>
7. **COVID-19 Pandemic: A Neurological Perspective.** *Cureus* 2020; 12:e7889 Lahiri D, Ardila A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489743>
8. **A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details.** *Eur. J. Neurol.* 2020; Romoli M, Jelcic I, Bernard-Valnet R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503088>
9. **COVID-19 breakthroughs: separating fact from fiction.** *Febs j* 2020; Dhillon P, Breuer M, Hirst N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500928>
10. **Beyond COVID-19: How the 'dismal science' can prepare us for the future.** *Health Econ.* 2020; Chilton S, Nielsen JS, Wildman J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488905>
11. **Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.** *Integr Med Res* 2020; 9:100426 Yang M, Shang YX, Tian ZY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483523>
12. **Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of COVID-19.** *J. Am. Acad. Child Adolesc. Psychiatry* 2020; Loades ME, Chatburn E, Higson-Sweeney N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504808>
13. **COVID-19: Considerations of Diabetes and Cardiovascular Disease Management.** *J. Diabetes Sci. Technol.* 2020:1932296820930025 Ceriello A, Schnell O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475168>
14. **SARS, MERS and COVID-19 among healthcare workers: A narrative review.** *J Infect Public Health* 2020; Xiao J, Fang M, Chen Q, He B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493671>
15. **SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences.** *J Med Virol* 2020; Lotfi M, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492197>
16. **COVID-19 presenting with immune thrombocytopenia: a case report and review of the literature.** *J Med Virol* 2020; Murt A, Eskazan AE, Yilmaz U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497344>
17. **Influenza and COVID-19 Co-infection: Report of 6 cases and review of the Literature.** *J Med Virol* 2020; Ozaras R, Cirpin R, Duran A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497283>
18. **Novel therapeutic approaches for treatment of COVID-19.** *J. Mol. Med. (Berl.)* 2020; Hossein-Khannazer N, Shokohian B, Shpichka A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494931>
19. **What orthopedic surgeons need to know about Covid-19 pandemic.** *J Orthop* 2020; 21:275-277 Emara K, Emara AK, Farhan M, Mahmoud S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501382>

20. **COVID-19 update: Covid-19-associated coagulopathy.** *J. Thromb. Thrombolysis* 2020; Becker RC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32415579>
21. **The immune system and COVID-19: Friend or foe?** *Life Sci* 2020;117900Yazdanpanah F, Hamblin MR, Rezaei N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502542>
22. **What would Sergio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?** *Med. Hypotheses* 2020; 143:109886Nicolau LAD, Magalhaes PJC, Vale ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504925>
23. **An update of treatments against COVID-19. SARS-CoV-2 pandemic.** *MMW-Fortschritte der Medizin* 2020; 162:20-23Müller T.
24. **COVID-19: the vasculature unleashed.** *Nat. Rev. Immunol.* 2020; Teuwen LA, Geldhof V, Pasut A, Carmeliet P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32439870>
25. **The neurological manifestations of COVID-19: a review article.** *Neurol Sci* 2020; Niazkar HR, Zibae B, Nasimi A, Bahri N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483687>
26. **A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions.** *Pathogens* 2020; 9Neerukonda SN, Katneni U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485970>
27. **Clinical Manifestations of Children with COVID-19: a Systematic Review.** *Pediatr Pulmonol* 2020; de Souza TH, Nadal JA, Nogueira RJN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492251>
28. **SARS-CoV-2 and COVID-19: between pathophysiology complexity and therapeutic uncertainty.** *Physiol Rev* 2020; Romagnoli S, Peris A, de Gaudio AR, Geppetti P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496872>
29. **A systematic review of chest imaging findings in COVID-19.** *Quant Imaging Med Surg* 2020; 10:1058-1079Sun Z, Zhang N, Li Y, Xu X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489929>
30. **Paediatric aspects of COVID-19: An update.** *Respir Med Res* 2020; 78:100765Kammoun R, Masmoudi K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504982>
31. **Thrombosis risk associated with COVID-19 infection. A scoping review.** *Thromb Res* 2020; 192:152-160Al-Ani F, Chehade S, Lazo-Langner A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485418>
32. **An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies.** *Travel Med Infect Dis* 2020:101755Dhama K, Patel SK, Pathak M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479816>
33. **Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review.** *World J. Gastroenterol.* 2020; 26:2323-2332Cha MH, Regueiro M, Sandhu DS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476796>

## Risk factors (41 articles)

1. **ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy.** *Aging (Albany NY)* 2020; 12Asselta R, Paraboschi EM, Mantovani A, Duga S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501810>
2. **Comparison of clinical characteristics and outcomes of patients with coronavirus disease 2019 at different ages.** *Aging (Albany NY)* 2020; 12Zhao M, Wang M, Zhang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499448>
3. **Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis.** *Aging Dis* 2020; 11:668-678Liu H, Chen S, Liu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489711>
4. **Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors.** *Allergy* 2020; Radzikowska U, Ding M, Tan G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496587>
5. **Cholesterol: A new game player accelerating endothelial injuries caused by SARS-CoV-2?** *Am J Physiol Endocrinol Metab* 2020; Cao X, Yin R, Albrecht H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501731>
6. **Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?** *Am J Physiol Endocrinol Metab* 2020; 318:E890-e891Rocha JC, Calhau C, MacDonald A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479158>
7. **Understanding the age divide in COVID-19: Why are children overwhelmingly spared?** *Am J Physiol Lung Cell Mol Physiol* 2020; Lingappan K, Karmouty-Quintana H, Davies J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32491949>
8. **Hematological findings in coronavirus disease 2019: indications of progression of disease.** *Ann. Hematol.* 2020; Liu X, Zhang R, He G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495027>
9. **Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19.** *Biomark. Med.* 2020; Li J, Li M, Zheng S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490680>
10. **Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.** *Biomed. Pharmacother.* 2020; 128:110296Ghafouri-Fard S, Noroozi R, Vafaei R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480226>
11. **Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.** *Cell* 2020; Shen B, Yi X, Sun Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492406>
12. **Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?** *Clin Rheumatol* 2020; Vakili-Gilani K, O'Rourke K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474884>
13. **Biomarkers associated with COVID-19 disease progression.** *Crit. Rev. Clin. Lab. Sci.* 2020:1-11Ponti G, Maccaferri M, Ruini C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503382>
14. **Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 infection.** *Diabetes Obes. Metab.* 2020; Wu J, Zhang J, Sun X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496012>
15. **Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.** *Emerg Microbes Infect* 2020; 9:1123-1130Han H, Ma Q, Li C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475230>
16. **Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.** *Emerg Microbes Infect* 2020; 9:1096-1101Shen L, Wang C, Zhao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476607>

17. **Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.** *Eur Heart J* 2020; Gao C, Cai Y, Zhang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498076>
18. **Active smoking and severity of coronavirus disease 2019 (COVID-19): Differences in measurement of variables could cause errors in the results.** *Eur J Intern Med* 2020; Jj S, N A, E G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499172>
19. **Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.** *In Vivo* 2020; 34:1589-1592 Smetana K, Jr., Brabek J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503815>
20. **Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico.** *J. Clin. Endocrinol. Metab.* 2020; Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474598>
21. **Elevated serum aspartate aminotransferase level identifies patients with coronavirus disease 2019 and predicts the length of hospital stay.** *J. Clin. Lab. Anal.* 2020:e23391 Gu X, Li X, An X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32488888>
22. **Using Machine Learning to Predict ICU Transfer in Hospitalized COVID-19 Patients.** *J Clin Med* 2020; 9 Cheng FY, Joshi H, Tandon P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492874>
23. **Estimating the Risk of COVID-19 Death During the Course of the Outbreak in Korea, February-May 2020.** *J Clin Med* 2020; 9 Shim E, Mizumoto K, Choi W, Chowell G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485871>
24. **COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?** *J. Endocrinol. Invest.* 2020; Filardi T, Morano S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495299>
25. **Drinking no-links to the severity of COVID-19: a systematic review and meta-analysis.** *J Infect* 2020; Liu M, Gao Y, Shi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474047>
26. **The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis.** *J Infect* 2020; Liu M, Gao Y, Zhang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502509>
27. **Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19.** *J Infect* 2020; Nguyen Y, Corre F, Honsel V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474039>
28. **Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.** *J Infect* 2020; Peng HC, Hussin N, Nalliah S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474031>
29. **Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States.** *J Intern Med* 2020; Imam Z, Odish F, Gill I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498135>
30. **"Determining Host Factors Contributing to Disease Severity in a Family Cluster of 29 Hospitalized SARS-CoV-2 Patients: Could Genetic Factors Be Relevant in the Clinical Course of COVID-19?"** *J Med Virol* 2020; Ikitimur H, Borku Uysal B, Cengiz M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492209>
31. **Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan.** *J Med Virol* 2020; Qin L, Li X, Shi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497297>
32. **Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV (or SARS-CoV-2) Infection.** *J Med Virol* 2020; Zhuang MW, Cheng Y, Zhang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497323>
33. **Acute pulmonary embolism in COVID-19 related hypercoagulability.** *J. Thromb. Thrombolysis* 2020; Lorenzo C, Francesca B, Francesco P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474757>
34. **Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.** *JCI Insight* 2020; Zhao Y, Qin L, Zhang P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501293>
35. **Could autism spectrum disorders be a risk factor for COVID-19?** *Med. Hypotheses* 2020; 144:109899 Lima MES, Barros LCM, Aragao GF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32505067>
36. **The role of selectivity of the SARS-CoV-2 virus for human genetic profiles in susceptibility and resistance to COVID-19.** *New Microbes New Infect* 2020; 36:100697 Khan FA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483490>
37. **Predicting COVID-19 Incidence Using Anosmia and Other COVID-19 Symptomatology: Preliminary Analysis Using Google and Twitter.** *Otolaryngol Head Neck Surg.* 2020:194599820932128 Panuganti BA, Jafari A, MacDonald B, DeConde AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484425>
38. **Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study.** *Pharmacol. Res.* 2020:104965 Russo V, Di Maio M, Attena E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474087>
39. **Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study.** *Theranostics* 2020; 10:6372-6383 Xu PP, Tian RH, Luo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483458>
40. **Descriptive characteristics of hospitalized adult smokers and never-smokers with COVID-19.** *Tob Induc Dis* 2020; 18:46 Kalan ME, Ghobadi H, Taleb ZB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489343>
41. **The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.** *Turk J Med Sci* 2020; Goker H, Aladag Karakulak E, Demiroglu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496734>

## Safety (17 articles)

1. **Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19.** *Circulation* 2020; Mazzanti A, Briani M, Kukavica D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501756>
2. **Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.** *Clin Transl Sci* 2020; Irie K, Nakagawa A, Fujita H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475019>
3. **Renin-Angiotensin-System (RAS) and COVID-19 - On the Prescription of RAS Blockers.** *Deutsche Medizinische Wochenschrift* 2020; 145:682-686 Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F.
4. **Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.** *Eur Heart J* 2020; Gao C, Cai Y, Zhang K *et al.*



- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498076>
5. **Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection.** *Eur. J. Haematol.* 2020; Afra TP, Nampoothiri RV, Razmi TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500556>
  6. **Comparative impacts of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality.** *Hypertension* 2020; Zhou F, Liu YM, Xie J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493070>
  7. **COVID-19: An Alert to Ventilator-Associated Bacterial Pneumonia.** *Infect Dis Ther* 2020; Povia HCC, Chianca GC, Iorio N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474891>
  8. **Risk of using hydroxychloroquine as a treatment of COVID-19.** *Int. J. Risk Saf. Med.* 2020; Alanagreh L, Alzoughool F, Atoum M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474476>
  9. **Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.** *J Cardiovasc Electrophysiol* 2020; Maraj I, Hummel JP, Taoutel R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485061>
  10. **Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?** *J. Diabetes Sci. Technol.* 2020:1932296820932155Koufakis T, Metallidis S, Zebekakis P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486846>
  11. **COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?** *J. Endocrinol. Invest.* 2020; Filardi T, Morano S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495299>
  12. **HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.** *J Public Health (Oxf)* 2020; Nagaraja BS, Ramesh KN, Dhar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490532>
  13. **Probiotics and COVID-19: is there any link?** *Lett. Appl. Microbiol.* 2020; Akour A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495940>
  14. **First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.** *Liver Int* 2020; Muhovic D, Bojovic J, Bulatovic A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478465>
  15. **Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.** *Nutrients* 2020; 12Mehmel M, Jovanovic N, Spitz U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486488>
  16. **Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.** *Saf Sci* 2020; 129:104842Karalis V, Ismailos G, Karatza E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501367>
  17. **[Pharmacovigilance study on drug-induced cardiac injury during treatment of COVID-19].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:2275-2286Zhang D, Lyu JT, Zhang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495580>

## Treatment options (100 articles)

1. **Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.** *ACS Chem Neurosci* 2020; Yin XX, Zheng XR, Peng W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485101>
2. **Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.** *Aging Dis* 2020; 11:465-469Gentile P, Sterodimas A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489692>
3. **Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?** *Aging Dis* 2020; 11:477-479Ozturk S, Elcin AE, Elcin YM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489694>
4. **Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.** *Ann. Clin. Microbiol. Antimicrob.* 2020; 19:23Sharun K, Dhama K, Patel SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473642>
5. **S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19.** *Arch Med Res* 2020; Arafah A, Ali S, Yattoo AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493626>
6. **Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.** *Arch Med Res* 2020; Saha A, Sharma AR, Bhattacharya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482373>
7. **Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2.** *Arch Med Res* 2020; Satarker S, Nampoothiri M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493627>
8. **Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells.** *Biomedicines* 2020; 8Park JB, Peters R, Pham Q, Wang TTY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485858>
9. **A lesson from a saboteur: high molecular weight kininogen (HMWK) impact in COVID-19.** *Br. J. Pharmacol.* 2020; Colarusso C, Terlizzi M, Pinto A, Sorrentino R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497257>
10. **The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic.** *Carbohydr Polym* 2020; 240:116346Cao P, Wu S, Wu T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475597>
11. **The potential insights of Traditional Chinese Medicine on treatment of COVID-19.** *Chin. Med.* 2020; 15:51Tong T, Wu YQ, Ni WJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483409>
12. **Can an Old Ally Defeat a New Enemy?** *Circulation* 2020; Gurbel PA, Bliden KP, Schror K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478567>
13. **Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19.** *Circulation* 2020; Mazzanti A, Briani M, Kukavica D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501756>
14. **Treating COVID-19 with colchicine in community healthcare setting.** *Clin Immunol* 2020; 217:108490Della-Torre E, Della-Torre F, Kusanovic M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492478>
15. **Treating COVID-19 with colchicine in community healthcare setting.** *Clin Immunol* 2020:108490Della-Torre E, Della-Torre F, Kusanovic Pcp M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492478>
16. **Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter?** *Clin Infect Dis* 2020; Ippolito MM, Flexner C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474576>

17. **Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients.** *Clin Infect Dis* 2020; Wang X, Guo X, Xin Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497196>
18. **Does vitamin D deficiency increase the severity of COVID-19?** *Clin Med (Lond)* 2020; Weir EK, Thenappan T, Bhargava M, Chen Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503801>
19. **Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?** *Clin Rheumatol* 2020; Ibanez S, Martinez O, Valenzuela F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495226>
20. **Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.** *Clin Transl Sci* 2020; Irie K, Nakagawa A, Fujita H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475019>
21. **Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.** *Cureus* 2020; 12:e8342Bhagavathula AS, Aldhaleei WA, Rovetta A, Rahmani J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494546>
22. **Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study.** *Curr Med Sci* 2020; Zhang JN, Wang WJ, Peng B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474860>
23. **Potential role of Anti-IL-17 in COVID-19 treatment.** *Dermatol Ther* 2020:e13715Ayhan E, Ozturk M, An I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475041>
24. **Renin-Angiotensin-System (RAS) and COVID-19 - On the Prescription of RAS Blockers.** *Deutsche Medizinische Wochenschrift* 2020; 145:682-686Kreutz R, Abd El-Hady Algharably E, Ganten D, Messerli F.
25. **Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.** *Epigenomics* 2020; Ayaz S, Crea F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495654>
26. **Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection.** *Eur. J. Haematol.* 2020; Afra TP, Nampoothiri RV, Razmi TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500556>
27. **Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.** *Eur J Intern Med* 2020; Campocharo C, Della-Torre E, Cavalli G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482597>
28. **Does lopinavir measure up in the treatment of Covid-19?** *Expert Opin Investig Drugs* 2020; Doggrell SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475183>
29. **Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.** *Gut* 2020; Janowitz T, Gablenz E, Pattinson D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32499303>
30. **NLR: A Cost-effective Nomogram to Guide Therapeutic Interventions in COVID-19.** *Immunol. Invest.* 2020:1-9Kerboua KE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32482134>
31. **COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.** *In Vivo* 2020; 34:1567-1588Andreou A, Trantza S, Filippou D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503814>
32. **Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.** *In Vivo* 2020; 34:1597-1602Bimonte S, Crispo A, Amore A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503817>
33. **Oral Methioninase for Covid-19 Methionine-restriction Therapy.** *In Vivo* 2020; 34:1593-1596Hoffman RM, Han Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503816>
34. **Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.** *In Vivo* 2020; 34:1589-1592Smetana K, Jr., Brabek J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503815>
35. **Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?** *Indian J. Public Health* 2020; 64:S125-s127Nina PB, Dash AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496241>
36. **Empirical Treatment and Prevention of COVID-19.** *Infect Chemother* 2020; Shin HS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32476308>
37. **Tocilizumab administration in a refractory case of COVID-19.** *Int J Antimicrob Agents* 2020:106043Dastan F, Nadji SA, Saffaei A, Tabarsi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502524>
38. **Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.** *Int J Cardiol* 2020; Frigerio M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473921>
39. **Lack of Antiviral Activity of Darunavir against SARS-CoV-2.** *Int J Infect Dis* 2020; De Meyer S, Bojkova D, Cinatl J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479865>
40. **Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.** *Int J Mol Sci* 2020; 21Hagar M, Ahmed HA, Aljohani G, Alhaddad OA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486229>
41. **Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.** *Int J Mol Sci* 2020; 21Wang X, Xia S, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32481690>
42. **Risk of using hydroxychloroquine as a treatment of COVID-19.** *Int. J. Risk Saf. Med.* 2020; Alanagreh L, Alzoughool F, Atoum M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474476>
43. **Convalescent plasma therapy in the treatment of COVID-19: practical considerations: Correspondence.** *Int J Surg* 2020; Islam A, Rafiq S, Karim S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502707>
44. **Antiviral Effects of Probiotic metabolites on COVID-19.** *J Biomol Struct Dyn* 2020:1-11Anwar F, Altayb HN, Al-Abbasi FA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32475223>
45. **Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.** *J Cardiovasc Electrophysiol* 2020; Maraj I, Hummel JP, Taoutel R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32485061>
46. **Interleukin-17: a potential therapeutic target in COVID-19.** *J Infect* 2020; Mendoza VMM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504739>
47. **Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.** *J Infect* 2020; Peng HC, Hussin N, Nalliah S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474031>
48. **Does type of immunosuppression influence the course of Covid-19 infection?** *J Infect* 2020; Razanamahery J, Soumagne T, Humbert S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504741>

49. **ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.** *J. Med. Toxicol.* 2020; Stolbach AI, Mazer-Amirshahi M, Marino R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500283>
50. **"Tocilizumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients".** *J Med Virol* 2020; Borku Uysal B, Ikitimur H, Yavuzer S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484930>
51. **Feasibility of Tocilizumab in ICU patients with COVID-19.** *J Med Virol* 2020; Issa N, Dumery M, Guisset O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32484915>
52. **Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion.** *J Med Virol* 2020; Shabani M, Shokouhi S, Moradi O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492210>
53. **COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.** *J Med Virol* 2020; Yu T, Tian C, Chu S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492205>
54. **A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.** *J Med Virol* 2020; Zhang Z, Wang S, Tu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501538>
55. **Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.** *J Med Virol* 2020; Zuo Y, Liu Y, Zhong Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492211>
56. **Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?** *J Microbiol Immunol Infect* 2020; Owa AB, Owa OT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474026>
57. **Novel therapeutic approaches for treatment of COVID-19.** *J. Mol. Med. (Berl.)* 2020; Hossein-Khannazer N, Shokoohian B, Shpichka A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494931>
58. **HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.** *J Public Health (Oxf)* 2020; Nagaraja BS, Ramesh KN, Dhar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490532>
59. **Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.** *Life Sci* 2020:117905Banu N, Panikar SS, Leal LR, Leal AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504757>
60. **First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.** *Liver Int* 2020; Muhovic D, Bojovic J, Bulatovic A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478465>
61. **Nebulized Lidocaine in COVID-19, An Hypothesis.** *Med. Hypotheses* 2020; 144:109947Ali ZA, El-Mallakh RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32505070>
62. **Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.** *Med. Hypotheses* 2020; 144:109910Caruso AA, Del Prete A, Lazzarino AI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32505069>
63. **N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.** *Med. Hypotheses* 2020; 143:109862Poe FL, Corn J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32504923>
64. **Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.** *Med. Hypotheses* 2020; 143:109891Unal G, Turan B, Balcioglu YH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498007>
65. **Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.** *Metabolism* 2020:154282Dalamaga M, Karampela I, Mantzoros CS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497535>
66. **An update of treatments against COVID-19. SARS-CoV-2 pandemic.** *MMW-Fortschritte der Medizin* 2020; 162:20-23Müller T.
67. **With IL-6 inhibitor against COVID-19: Corona pandemic.** *MMW-Fortschritte der Medizin* 2020; 162:65Red.
68. **Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.** *Nanomaterials (Base)* 2020; 10Nasrollahzadeh M, Sajjadi M, Soufi GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32486364>
69. **Reply: "Vitamin D Supplementation in Influenza and COVID-19 Infections. Comment on: Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths *Nutrients* 2020, 12(4), 988".** *Nutrients* 2020; 12Grant WB, Baggerly CA, Lahore H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492787>
70. **Angiotensin converting enzyme 2 (ACE2) and COVID-19: using antihypertensive medications, pharmacogenetic considerations.** *Pharmacogenomics* 2020; Snyder EM, Johnson BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501190>
71. **Estimated Inactivation of Coronaviruses by Solar Radiation With Special Reference to COVID-19.** *Photochem. Photobiol.* 2020; Sagripanti JL, Lytle CD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502327>
72. **Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations.** *Saf Sci* 2020; 129:104842Karalis V, Ismailos G, Karatza E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501367>
73. **Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.** *SLAS Discov* 2020:2472555220934421Scalise M, Indiveri C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500793>
74. **Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.** *Theranostics* 2020; 10:5932-5942Itani R, Tobaiqy M, Al Faraj A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483428>
75. **Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence.** *Therapie* 2020; Roustit M, Guilhaumou R, Molimard M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32473812>
76. **Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.** *Transfus. Apher. Sci.* 2020:102821Cinar OE, Sayinalp B, Aladag Karakulak E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32487513>
77. **Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:475Barnabas RV, Brown E, Bershteyn A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493478>



78. **Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:491 Bosteels C, Maes B, Van Damme K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503663>
79. **Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.** *Trials* 2020; 21:489 Dalili N, Kashefzadeh A, Nafar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503620>
80. **Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.** *Trials* 2020; 21:462 Gorman E, Shankar-Hari M, Hopkins P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493473>
81. **Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:473 Irvani SSN, Golmohammadi M, Pourhoseingholi MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493468>
82. **The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:488 Li J, Zhang C, Wu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503657>
83. **Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:485 Lyngbakken MN, Berdal JE, Eskesen A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503662>
84. **Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:468 Maes B, Bosteels C, De Leeuw E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493441>
85. **Umbilical cord blood therapy to prevent progression of COVID-19 related pneumonia: a structured summary of a study protocol for a pilot randomised controlled trial.** *Trials* 2020; 21:474 Malhotra A, Ernest D, Rogers BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493459>
86. **Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:467 Pirjani R, Soori T, Dehpour AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493447>
87. **A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:470 Rilinger J, Kern WV, Duerschmied D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493514>
88. **Two Randomized Controlled Trials of Bacillus Calmette-Guerin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials.** *Trials* 2020; 21:481 Ten Doesschate T, Moorlag S, van der Vaart TW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503602>
89. **Response to letter to the editor: radiological approaches to COVID-19 pneumonia.** *Turk J Med Sci* 2020; Akcay MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490639>
90. **Letter to the Editor: Radiological approaches to COVID-19 pneumonia.** *Turk J Med Sci* 2020; Ufuk F, Savas R, Hazirolan T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490640>
91. **[Therapeutic effect of Compound Qinlan Oral Liquid on treating combining disease with syndrome of human coronavirus pneumonia with pestilence attacking lung syndrome].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:1473-1480 Bao YY, Shi YJ, Guo SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489023>
92. **[Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:1481-1487 Bian YQ, Ma J, Ren Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489024>
93. **[Analysis of 131 cases of COVID-19 treated with Ganlu Xiaodu Decoction].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:2232-2238 Chen L, Cheng ZQ, Liu F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495575>
94. **[Visual analysis of coronavirus disease 2019 (COVID-19) studies based on bibliometrics].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:2239-2248 Chen Y, Guo YB, Guo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495576>
95. **[Usage of ethnomedicine on COVID-19 in China].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:2265-2274 Li ZY, Tuya, Li HT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495579>
96. **[Rationality of Asari Radix et Rhizoma in Qingfei Paidu Decoction based on literature analysis].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:1515-1520 Qin ZN, Wang MX, Shi NN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489028>
97. **[Suggestions on design of evidence-based traditional Chinese medicine clinical study for new public health emergencies].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:2291-2295 Wang LX, Xie YM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495582>
98. **[Recent advances in treatment of viral pneumonia using Chinese patent medicine].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:1509-1514 Wang T, Han LF, Wang YF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489027>
99. **[Treatment of COVID-19 guided by holistic view of traditional Chinese medicine—therapy aimed at both viral and host].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:1521-1525 Yuan R, Xin QQ, Tang SH, Cong WH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32489029>
100. **[Pharmacovigilance study on drug-induced cardiac injury during treatment of COVID-19].** *Zhongguo Zhong Yao Za Zhi* 2020; 45:2275-2286 Zhang D, Lyu JT, Zhang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32495580>

1. **Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).** *Eur Heart J* 2020; Anker SD, Butler J, Khan MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498081>
2. **Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.** *Integr Med Res* 2020; 9:100426 Yang M, Shang YX, Tian ZY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32483523>
3. **Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study.** *Intern Emerg Med* 2020; Lapostolle F, Schneider E, Vianu I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32474850>
4. **Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.** *J Med Virol* 2020; Zuo Y, Liu Y, Zhong Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32492211>
5. **HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.** *J Public Health (Oxf)* 2020; Nagaraja BS, Ramesh KN, Dhar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32490532>
6. **Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:475 Barnabas RV, Brown E, Bershteyn A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493478>
7. **Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:472 Cuadrado-Lavin A, Olmos JM, Cifrian JM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493494>
8. **Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.** *Trials* 2020; 21:489 Dalili N, Kashefzadeh A, Nafar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503620>
9. **A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:466 Garcia IG, Rodriguez-Rubio M, Mariblanca AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493475>
10. **Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.** *Trials* 2020; 21:462 Gorman E, Shankar-Hari M, Hopkins P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493473>
11. **Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:473 Irvani SSN, Golmohammadi M, Pourhoseingholi MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493468>
12. **The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:488 Li J, Zhang C, Wu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503657>
13. **Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:485 Lyngbakken MN, Berdal JE, Eskesen A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503662>
14. **Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:468 Maes B, Bosteels C, De Leeuw E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493441>
15. **Umbilical cord blood therapy to prevent progression of COVID-19 related pneumonia: a structured summary of a study protocol for a pilot randomised controlled trial.** *Trials* 2020; 21:474 Malhotra A, Ernest D, Rogers BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493459>
16. **Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:467 Pirjani R, Soori T, Dehpour AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493447>
17. **A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:470 Rillinger J, Kern WV, Duerschmied D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493514>
18. **Two Randomized Controlled Trials of Bacillus Calmette-Guerin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials.** *Trials* 2020; 21:481 Ten Doesschate T, Moorlag S, van der Vaart TW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32503602>
19. **A short, animated video to improve good COVID-19 hygiene practices: a structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:469 Vandormael A, Adam M, Greuel M, Barnighausen T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32493460>

## Vaccines (5 articles)

1. **On setting expectations for a SARS-CoV-2 Vaccine.** *Clin Infect Dis* 2020; Canaday DH, Gravenstein S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497168>
2. **Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.** *Cureus* 2020; 12:e8342 Bhagavathula AS, Aldhalei WA, Rovetta A, Rahmani J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32494546>

3. **Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?** Hum Vaccin Immunother 2020;1-2Anbarasu A, Ramaiah S, Livingstone P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32501133>
4. **COVID-19 vaccine development and the way forward.** Indian J. Public Health 2020; 64:S108-s111Arora NK, Das MK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496238>
5. **Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.** Med. Hypotheses 2020; 143:109849Meenakshisundaram R, Senthilkumaran S, Thirumalaikulundusubramanian P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32480250>

## Women – pregnancy (10 articles)

1. **Preeclampsia-like syndrome induced by severe COVID-19: a prospective observational study.** Bjog 2020; Mendoza M, Garcia-Ruiz I, Maiz N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479682>
2. **Breastfeeding during the COVID-19 pandemic: suggestions on behalf of Woman Study Group of AMD.** Diabetes Res Clin Pract 2020;108239Giuliani C, Li Volsi P, Brun E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32479766>
3. **Universal screening for SARS-CoV-2 in asymptomatic obstetric patients in Tokyo, Japan.** Int J Gynaecol Obstet 2020; Ochiai D, Kasuga Y, Iida M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32496574>
4. **Rheumatic diseases during pregnancy and SARS-CoV-2: An appeal for medication adherence.** Int J Gynaecol Obstet 2020; Scioscia M, Praino E, Scioscia C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502303>
5. **Provisions for Obstetrics and Gynaecology - letter to the editor on "Impact of the coronavirus (COVID-19) pandemic on surgical practice - Part 2 (surgical prioritisation)": A correspondence.** Int J Surg 2020; Sookramanien SP, Sookramanien SR, Shubber N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32502706>
6. **Wet Nurses to Donor Milk Banks and Back Again: The Continuum of Sharing Our Milk to Save Lives.** J Hum Lact 2020; 36:213-216Marinelli KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32478620>
7. **Relationship between pregnancy and coronavirus: what we know.** J Matern Fetal Neonatal Med 2020;1-12Forestieri S, Marcialis MA, Migliore L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498581>
8. **Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan.** J Med Virol 2020; Qin L, Li X, Shi J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32497297>
9. **Clinical update on COVID-19 in pregnancy: A review article.** J. Obstet. Gynaecol. Res. 2020; Ryeane GA, Purandare NC, McAuliffe FM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32500549>
10. **Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Espanola de Ginecologia y Obstetricia and Sociedad Espanola de Trombosis y Hemostasia.** Maturitas 2020; 137:57-62Ramirez I, De la Viuda E, Baquedano L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32498938>

---

to subscribe click [here](#)

---